



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12Q 1/68, C07H 21/02, C12P 15/00, XXXX XXX/XXXX X	A1	(11) International Publication Number: WO 00/26411 (43) International Publication Date: 11 May 2000 (11.05.2000)
(21) International Application Number: PCT/US99/25680 (22) International Filing Date: 01 November 1999 (01.11.1999) (30) Priority Data: 60/106,662 02 November 1998 (02.11.1998) US (60) Parent Application or Grant LYNX THERAPEUTICS, INC. [/]; O. WILLIAMS, Steven, R. [/]; O. KIRCHNER, James, J. [/]; O. DUBRIDGE, Robert, B. [/]; O. WILLIAMS, Steven, R. [/]; O. KIRCHNER, James, J. [/]; O. DUBRIDGE, Robert, B. [/]; O. GORTHEY, LeeAnn ; O.		Published
(54) Title: METHOD FOR MAKING COMPLEMENTARY OLIGONUCLEOTIDE TAG SETS (54) Titre: TECHNIQUE PERMETTANT D'OBTENIR DES ENSEMBLES DE MARQUEURS OLIGONUCLEOTIDIQUES COMPLEMENTAIRES (57) Abstract <p>The invention provides a method of synthesizing a repertoire of oligonucleotide tags comprising the steps of synthesizing a repertoire of oligonucleotide tag complements on one or more solid phase supports, cleaving a fraction of the oligonucleotide tag complements from the support(s), and inserting the cleaved tag complements into a cloning vector, as depicted in the figure. The cloned tag complements can conventionally be conjugated to selected polynucleotides to produce tagged polynucleotides having unique tag sequences which can be captured and sorted by hybridization to corresponding tag complements. Also provided are various reagents and components that are used or produced in the method.</p> (57) Abrégé <p>L'invention concerne une technique de synthèse d'un répertoire de marqueurs oligonucléotidiques comprenant une étape de synthèse d'un répertoire de compléments de marqueurs oligonucléotidiques sur un ou plusieurs supports de phase solide, une étape consistant à séparer du(des) support(s), par clivage, une fraction des compléments de marqueurs oligonucléotidiques et une étape d'introduction des compléments de marqueurs séparées par clivage dans un vecteur de clonage, tel que représenté par la figure. Les compléments de marqueurs clonés peuvent être conjugués à des polynucléotides sélectionnés afin de produire des polynucléotides marqués ayant des séquences uniques de marqueurs qui peuvent être piégées et triées par hybridation avec les compléments de marqueurs correspondants. L'invention concerne aussi différents réactifs et composants utilisés ou produits par cette technique.</p>		

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68, C07H 21/02, C12N 19/34, C12P 15/00		A1	(11) International Publication Number: WO 00/26411 (43) International Publication Date: 11 May 2000 (11.05.00)
(21) International Application Number: PCT/US99/25680 (22) International Filing Date: 1 November 1999 (01.11.99) (30) Priority Data: 60/106,662 2 November 1998 (02.11.98) US (71) Applicant (for all designated States except US): LYNX THERAPEUTICS, INC. [US/US]; 25861 Industrial Boulevard, Hayward, CA 94545 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): WILLIAMS, Steven, R. [US/US]; 3094 Market Street, San Francisco, CA 94114 (US). KIRCHNER, James, J. [US/US]; 280 Waverly Street #5, Menlo Park, CA 94025 (US). DUBRIDGE, Robert, B. [US/US]; 825 Holly Road, Belmont, CA 94002 (US). (74) Agents: GORTHEY, LeeAnn et al.; Dehlinger & Associates, P.O. Box 60850, Palo Alto, CA 94306-0850 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CK, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	

(54) Title: METHOD FOR MAKING COMPLEMENTARY OLIGONUCLEOTIDE TAG SETS

(57) Abstract

The invention provides a method of synthesizing a repertoire of oligonucleotide tags comprising the steps of synthesizing a repertoire of oligonucleotide tag complements on one or more solid phase supports, cleaving a fraction of the oligonucleotide tag complements from the support(s), and inserting the cleaved tag complements into a cloning vector, as depicted in the figure. The cloned tag complements can conventionally be conjugated to selected polynucleotides to produce tagged polynucleotides having unique tag sequences which can be captured and sorted by hybridization to corresponding tag complements. Also provided are various reagents and components that are used or produced in the method.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

5

10

15

20

25

30

35

40

45

50

55

Method for Making Complementary Oligonucleotide Tag Sets**Field of the Invention**

The present invention relates generally to methods for synthesizing collections of oligonucleotide tags which may be used for identifying, sorting, and/or tracking molecules, especially polynucleotides. In a particular aspect, the present invention relates to a method for forming complementary sets of oligonucleotide tags and tag complements, which are particularly useful in immobilizing tagged entities on addressable arrays of tag complements.

Background of the Invention

Specific hybridization of oligonucleotides and their analogs is a fundamental process that is employed in a wide variety of research, medical, and industrial applications, including the identification of disease-related polynucleotides in diagnostic assays, screening for clones of novel target polynucleotides, identification of specific polynucleotides in blots of mixtures of polynucleotides, amplification of specific target polynucleotides, therapeutic blocking of inappropriately expressed genes, DNA sequencing, and the like, e.g. Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edition (Cold Spring Harbor Laboratory, New York, 1989); Keller and Manak, *DNA Probes*, 2nd Edition (Stockton Press, New York, 1993); Milligan et al., *J. Med. Chem.*, 36: 1923-1937 (1993); Drmanac et al., *Science*, 260: 1649-1652 (1993); Bains, J., *DNA Sequencing and Mapping*, 4: 143-150 (1993).

Specific hybridization has also been proposed as a method of tracking, retrieving, and identifying compounds labeled with oligonucleotide tags, e.g. Brenner, *International App. No. PCT/US95/12791* (Pub. No. WO 96/12014); Church et al., *Science*, 240: 185-188 (1988); Brenner and Lerner, *Proc. Natl. Acad. Sci.*, 89: 5381-5383 (1992); Alper, *Science*, 264: 1399-1401 (1994); and Needels et al., *Proc. Natl. Acad. Sci.*, 90: 10700-10704 (1993). The successful implementation of such tagging schemes depends in large part on the success in achieving specific hybridization between a tag and its complementary probe. That is, for an oligonucleotide tag to successfully identify a substance, the number of false positive and false negative signals must be minimized. Unfortunately, such spurious signals are not uncommon because base pairing and base stacking free energies vary widely among nucleotides in a duplex or triplex structure. For example, a duplex consisting of a repeated sequence of deoxyadenosine (A) and thymidine (T) bound to its complement may have less stability than an equal-length duplex consisting of a repeated sequence of deoxyguanosine (G) and deoxycytidine (C) bound to a partially complementary target containing a mismatch. Thus, if a desired compound from a large combinatorial chemical library were tagged with the former oligonucleotide, a significant possibility would exist that, under hybridization conditions designed to detect perfectly matched AT-rich duplexes, undesired compounds labeled with the GC-rich oligonucleotide, even in a mismatched duplex, would be detected along with the perfectly matched duplexes consisting of the AT-rich tag. Even though

reagents, such as tetramethylammonium chloride, are available to negate base-specific stability differences of oligonucleotide duplexes, the effect of such reagents is often limited, and their presence can be incompatible with, or render more difficult, further manipulations of the selected compounds, e.g. amplification by polymerase chain reaction (PCR), or the like. Such problems have been addressed by Brenner, as described in WO 96/12014 (supra) and International App. No. PCT/US96/09513 (WO 96/41011), in the development of minimally cross-hybridizing oligonucleotide tag sets which minimize the occurrence of mismatch hybridization.

Unfortunately, however, current methods of solid phase oligonucleotide synthesis, although highly efficient, still result in a significant fraction of failure sequences, particularly when oligonucleotides exceed 30 to 40 nucleotides in length. When mixtures of such oligonucleotides are employed as tags, particularly for sorting, an important consequence of failure sequences is that a fraction of the tags will not have complements whenever the two compounds are synthesized separately. Thus, in the sorting of complex mixtures, e.g. as called for in the process described in Brenner (cited above), such failures will limit the completeness of the sorting process.

In view of the above, it would be useful if there were available a means for synthesizing sets of oligonucleotide tags that would ensure that every tag had a complement regardless of the efficiency of the synthetic process employed.

Summary of the Invention

An object of the present invention is to provide a method of synthesizing one or more repertoires of oligonucleotide tags that ensures that every oligonucleotide tag in a repertoire will have a corresponding tag complement.

Another object of the invention is to provide a system for sorting polynucleotides onto solid phase supports by way of oligonucleotide tags produced by the method of the invention.

A further object of the invention is to provide a method of synthesizing oligonucleotide tags by the combinatorial addition of subunits (words).

These and other objects of the invention are achieved by providing a method of synthesis comprising the steps of synthesizing a repertoire of oligonucleotide tag complements on one or more solid phase supports, cleaving a fraction of the oligonucleotide tag complements from the support(s), and inserting the cleaved tag complements into a cloning vector. The cloned tag complements can conveniently be conjugated to selected substances, preferably biomolecules such as polynucleotides or polypeptides, to produce tagged substances having unique tag sequences which can be captured and sorted by hybridization to corresponding tag complements.

In one embodiment, the invention provides a method of synthesizing a repertoire of oligonucleotide tags. In the method, a plurality of different sequence oligonucleotide populations are synthesized on one or more solid phase supports, such that each population is located at a spatially discrete region relative to the

5 other populations, and the oligonucleotides in each population comprise a tag-complement sequence that is the same for every oligonucleotide in a given population, but which may be different from the tag-complement sequence in every other oligonucleotide population. A fraction of the oligonucleotides are
10 cleaved from each population on the one or more supports, to release a mixture of different-sequence tag-complement oligonucleotides. A primer is annealed to each tag-complement oligonucleotide, and the
15 annealed primers are extended to form a duplex comprising a tag-complement strand and a complementary tag strand, such that the tag-complement strands or the duplexes thus formed comprise an oligonucleotide tag repertoire. In one preferred embodiment, the oligonucleotides are bound to the one or more supports by
20 their 3'-termini, and each oligonucleotide contains a universal primer-binding sequence on the 3'-side of the tag complement sequence. In another preferred embodiment, the fraction of oligonucleotides cleaved from each population is from 10 to 30%. According to yet another preferred embodiment, a selected fraction of each population of synthesized oligonucleotides is bound to the one or more supports via base-cleavable linkages.

The invention also includes a repertoire of tag oligonucleotides prepared as above.

15 Also provided is a method of forming a tag-vector library comprising multiple members from a tag repertoire. In the method, an oligonucleotide tag repertoire prepared as above is inserted by ligation into
25 multiple copies of a selected vector, to form a tag-vector library comprising members of the tag repertoire. The invention also includes a tag-vector library formed by the method.

30 The invention also includes a method of forming a library of tagged polynucleotide fragments. In the method, a tag-vector library from above is combined with a mixture of different polynucleotide fragments under ligation conditions effective to insert a polynucleotide fragment into each tag-vector at a site adjacent to a tag-sequence in each vector. The invention also includes a library of tagged polynucleotide fragments formed by the method.

35 In yet another aspect, the invention also includes a system for sorting polynucleotides. The system includes one or more solid phase supports on which are attached a plurality of oligonucleotide populations,
40 such that each population is located at a spatially discrete region on the one or more supports relative to the other populations, and the oligonucleotides in each population comprise a tag-complement sequence that is the same for every oligonucleotide in a given population. The system also includes a tag composition selected from the group consisting of a tag repertoire, a tag-vector library, or a library of tagged
30 polynucleotide fragments, which may be prepared as above.

45 The invention also provides a solid phase support comprising a plurality of immobilized oligonucleotides containing identical tag sequences, wherein at least one of the oligonucleotides is linked to the support by a cleavable linker, and at least one other of the oligonucleotides is linked to the support by a non-cleavable linker. In a first preferred embodiment, the support is a bead. In a second
35 preferred embodiment, the support comprises a planar array of addressable regions, each region
50 containing a plurality of immobilized oligonucleotides containing identical tag sequences, such that the

5 tag sequences in at least two of the regions are different from each other. Preferably, the cleavable linker is a base-labile linker. The solid phase supports of the invention are particularly useful for generating repertoires of tag oligonucleotides that are substantially complementary to the oligonucleotides immobilized on the supports.

10 5 Thus, the invention also includes a solid phase bead or particle comprising a population of oligonucleotides attached to the bead or particle, wherein the population comprises first and second classes of oligonucleotides which contain identical oligonucleotide sequences, and the oligonucleotides in the first class contain a cleavable linking moiety that permits selective cleavage of the first class of oligonucleotides from the support, without significantly cleaving the second class of oligonucleotides.

15 10 In another embodiment, the invention includes a mixture of solid phase beads or particles of the type described above, wherein at least two beads or particles in the mixture contain oligonucleotide populations with different tag-complement sequences.

20 These and other objects and features of the present invention will become more apparent from the following description and the appended drawings.

15 Brief Description of the Drawings

25 Figure 1 shows an exemplary pair of oligonucleotide linking structures bound to a solid phase bead, and a mechanism of cleaving one of the linkers to release an attached oligonucleotide containing a tag complement (TC1), while the other linker remains intact.

30 20 Figure 2 shows a general scheme for practicing one embodiment of the invention, wherein a portion of a repertoire of immobilized oligonucleotides containing different-sequence tag complements are cleaved from the solid phase support, converted to double-stranded form, and inserted into a cloning vector. A tag-vector (1) library is combined with a mixture of different polynucleotide fragments under ligation conditions effective to insert the different fragments at a site adjacent to a tag-sequence in each

35 25 vector, so that each sample fragment (S_n) becomes associated with a different tag (T_n). The tag-sample fragments may then be excised and/or amplified, and the tagged fragments sorted by hybridization to immobilized corresponding tag complements.

40 Detailed Description of the Invention

30 The present invention provides methods and reagents for synthesizing matched sets (also referred to as repertoires) of tags and tag complements having high complementarity with each other. Such matched sets are particularly useful for labeling and sorting tagged molecules for parallel operations such as sequencing, fingerprinting, or other types of analysis.

45 In one aspect of the invention, populations of oligonucleotides are synthesized wherein each population contains identical tag complements that are linked to a support by a mixture of cleavable and

50 non-cleavable linking moieties. The cleavable linker permits a portion of the oligonucleotides in each

population to be cleaved from the support to serve as templates for forming oligonucleotides whose sequences are perfectly complementary to the tag complements remaining on the support. By cleaving a portion of the tag complements from the one or more supports, and using the cleaved tag complements as templates to form complementary tags, the method produces matched tag and tag complement repertoires in greater yield and fidelity than previous methods. The invention therefore enhances hybridization specificity and tag sequence complexity relative to what is achieved when tags and their complements are synthesized independently.

The invention provides a substantial improvement in techniques that utilize oligonucleotide tags, by providing a method for enhancing the fidelity of synthesis of tag complements. Previously, tags were synthesized independently from tag complements, such that there was no assurance that all intended tags and tag complements were actually synthesized. In particular, previous polynucleotide synthesis methods were susceptible to significant or complete failures in one or more nucleotide addition steps, such that resultant tags or tag complements did not have the intended sequences and cannot hybridize perfectly with their intended partners. Defective synthesis of oligonucleotides can prevent tagged sample species from locating and hybridizing to the intended tag complements, resulting in loss of signal and/or underestimation of the abundance of the affected sample species. In addition, the presence of defective tag sequences could lead to cross-hybridization with other tags, interfering with hybridization of those tags to their corresponding complements. Moreover, the complexity of the tag repertoires and tag complement repertoires was diminished.

These problems are overcome by the present invention, by using a selected portion of immobilized tag complement sequences as templates to form a repertoire of corresponding tags. Ligation of the tags to sample selected sample substances, preferably biomolecules such as polynucleotides or polypeptides, yields a mixture of tagged substances (e.g., sample polynucleotide fragments) which can be captured on an array of tag complements. The invention thus provides a way of ensuring that a tag repertoire, or a subset of a repertoire, can hybridize to a full range of tag complements.

I. Definitions

"Tag" or "tag oligonucleotide" or "oligonucleotide tag" refers to an oligonucleotide that contains a nucleotide sequence capable of serving as an identifier label for an attached species, such as a sample oligonucleotide, and which is detectably distinguishable from other tags in a tag repertoire.

"Complement" or "tag complement" as used herein refers to an oligonucleotide to which an oligonucleotide tag specifically hybridizes to form a perfectly matched duplex or triplex. In embodiments where specific hybridization results in a triplex, the oligonucleotide tag may be selected to be either double-stranded or single-stranded. Thus, where triplexes are formed, the term "complement" is meant to encompass either a double stranded complement of a single stranded oligonucleotide tag or a single-stranded complement of a double-stranded oligonucleotide tag.

5 The term "oligonucleotide" as used herein means a linear oligomer of natural or modified
nucleosidic monomers, including deoxyribonucleosides and ribonucleosides. Usually monomers are
linked by phosphodiester bonds or analogs thereof (e.g., phosphorothioates, phosphoramidates,
10 phosphonates, peptide nucleic acids (N-derivatized glycine polymers), and the like) to form
5 oligonucleotides ranging in size from a few monomeric units, e.g. 3-4, to several tens of monomeric
units, and up to 100 monomeric units. Whenever an oligonucleotide is represented by a sequence of
letters, such as "ATGCCTG," it will be understood that the nucleotides are in 5'→3' order from left to
right and that "A" denotes deoxyadenosine, "C" denotes deoxycytidine, "G" denotes deoxyguanosine,
15 and "T" denotes thymidine, unless otherwise noted. Usually oligonucleotides of the invention comprise
the four natural nucleotides. However, they may also comprise non-natural nucleotide analogs. It is
clear to those skilled in the art when oligonucleotides having natural or non-natural nucleotides may be
employed, e.g. where processing by enzymes is called for, usually oligonucleotides consisting of
20 natural nucleotides are required.

"Polynucleotide" or "polynucleotide fragment" refers to a polymer containing two or more
15 nucleotides. "Polynucleotide" encompasses "oligonucleotide", although the length of a polynucleotide
can exceed 100 monomeric units.

"Perfectly matched" in reference to a duplex means that the poly- or oligonucleotide strands
making up the duplex form a double stranded structure with one other such that every nucleotide in
each strand undergoes Watson-Crick basepairing with a nucleotide in the other strand. The term also
30 encompasses the pairing of nucleoside analogs, such as deoxyinosine, nucleosides with 2-aminopurine
bases, and the like, that may be employed. In reference to a triplex, the term means that the triplex
consists of a perfectly matched duplex and a third strand in which every nucleotide undergoes
Hoogsteen or reverse Hoogsteen association with a basepair of the perfectly matched duplex.
35 Conversely, a "mismatch" in a duplex between a tag and an oligonucleotide means that a pair or triplet
25 of nucleotides in the duplex or triplex fails to undergo Watson-Crick and/or Hoogsteen and/or reverse
Hoogsteen bonding.

As used herein, "nucleoside" includes the natural nucleosides, including 2'-deoxy and 2'-hydroxyl
40 forms, as described in Kornberg and Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco. 1992).
"Analog" in reference to nucleosides includes synthetic nucleosides having modified base moieties
30 and/or modified sugar moieties, e.g. described by Scheit, Nucleotide Analogs (John Wiley, New York,
1980); Uhlman and Peyman, Chemical Reviews, 90: 543-584 (1990). or the like, with the only proviso
45 that they are capable of specific hybridization. Such analogs include synthetic nucleosides designed to
enhance binding properties, reduce complexity, increase specificity, and the like.

"Nucleotide" refers to a nucleoside or nucleoside analog having one or more phosphate groups (or
35 analog thereof) attached to a 5', 3', and/or 2'-hydroxyl, or a nucleoside contained in an oligonucleotide
or polynucleotide.
50

As used herein, "complexity" in reference to a population of polynucleotides means the number of different species of molecule present in the population.

As used herein, "repertoire" refers to a collection or mixture of difference-sequence oligonucleotides, e.g., comprising oligonucleotide tags or tag complements. A "repertoire" can have a defined complexity.

As used herein, "cleavable linking moiety" refers to a chemical group that is cleavable under selected chemical conditions. The term "cleavable linker" refers to a compound or chemical group that contains a cleavable linking moiety. For example, the term "cleavable linker" encompasses an activated form of a linker compound that can be coupled via a first linking functionality to a support, and via a second functionality to an oligonucleotide. The cleavable linker can contain a cleavable linking moiety, such as an ester group, which is cleavable under selected cleavage conditions.

II. Components

The following sub-sections discuss various components, e.g., materials and reagents, that may be used to practice various aspects of the present invention.

A. Solid Support

Solid phase supports for use with the invention can have any of a wide variety of forms, including microparticles, beads, membranes, slides, plates, micro-machined chips, and the like. Likewise, solid phase supports of the invention may comprise a wide variety of materials, including glass, plastic, silicon, alkanethiolate-derivatized gold, cellulose, low cross-linked and high cross-linked polystyrene, silica gel, polyamide, and the like. Preferably, either a population of discrete particles is employed, such that each particle has a uniform coating, or population, of complementary sequences for the same tag (and no other), or one or more supports are employed with spatially discrete regions, each region containing a uniform coating, or population, of sequences that are complementary to the same tag (and no other). In the latter embodiment, the area of the regions may vary according to particular applications. Usually, the regions range in area from several μm^2 , e.g. 3-5 μm^2 , to several hundred μm^2 , e.g. 100-500 μm^2 . Preferably, such regions are spatially discrete so that signals generated by events, e.g. fluorescent emissions, at adjacent regions can be resolved from each other by the detection system being employed. In some applications, it may be desirable to have regions with uniform coatings of more than one tag complement, e.g. for simultaneous sequence analysis, or for bringing separately tagged molecules into close proximity.

For example, a wide variety of microparticle supports may be used with the invention, including microparticles made of controlled pore glass (CPG), highly cross-linked polystyrene, acrylic copolymers, cellulose, nylon, dextran, latex, polyacrolein, and the like, disclosed in the following exemplary references: Meth. Enzymol., Section A, Vol. 44, pages 11-147, (Academic Press, New York, 1976); U.S. patents 4,678,814; 4,413,070; and 4,046,720; and Pon, Chapter 19, in Agrawal,

editor, *Methods in Molecular Biology*, Vol. 20, (Humana Press, Totowa, NJ, 1993). Microparticle supports further include commercially available nucleoside-derivatized CPG and polystyrene beads (e.g. available from Perkin-Elmer Applied Biosystems, Foster City, CA); derivatized magnetic beads; polystyrene grafted with polyethylene glycol (e.g., TentaGel™, Rapp Polymere, Tübingen, Germany); and the like. Selection of the support characteristics, such as material, porosity, size, shape, and the like, and the type of linking moiety employed will depend on the conditions under which the tags are used. For example, in applications involving successive processing with enzymes, supports and linkers that minimize steric hindrance of the enzymes and that facilitate access to substrate are preferred. Other important factors to be considered in selecting the most appropriate microparticle support include size uniformity, efficiency as a synthesis support, surface area, and optical properties. It is noted that smooth, clear (transparent) beads provide instrumental advantages when handling large numbers of beads on a surface.

As mentioned above, tag complements may also be synthesized on one or more solid phase supports to form an array of regions uniformly coated with tag complements. That is, within each region in such an array the same tag complement is synthesized. Techniques for synthesizing such arrays are now well known and are disclosed, for example, in McGall et al., PCT App. No. PCT/US93/03767 (WO 93/22680 (Affymax); Pease et al., *Proc. Natl. Acad. Sci.* 91:5022-5026 (1994); Southern and Maskos in PCT App. No. PCT/GB89/01114 (WO 90/03382 by Isis); Southern et al., *Genomics*, 13: 1008-1017 (1992); and Maskos and Southern, *Nucleic Acids Research*, 21:4663-4669 (1993).

Preferably, the invention is implemented with microparticles or beads uniformly coated with complements of the same tag sequence. Microparticle supports and methods of covalently or noncovalently linking oligonucleotides to their surfaces are well known, as exemplified by the following references: Beaucage and Iyer (cited above); Gait, editor, *Oligonucleotide Synthesis: A Practical Approach* (IRL Press, Oxford, 1984 and 1990 editions); and the references cited above. Generally, the size and shape of a microparticle is not critical; however, microparticles in the size range of a few, e.g. 1-2, to several hundred, e.g. 200-1000 μm diameter are preferable, as they facilitate the construction and manipulation of large repertoires of oligonucleotide tags with minimal reagent and sample usage.

In some preferred applications, commercially available controlled-pore glass (CPG) or polystyrene supports are employed as solid phase supports in the invention. Such supports come available with base-labile linkers and initial nucleosides attached, e.g. Applied Biosystems (Foster City, CA). Preferably, microparticles having pore size between 500 and 1000 angstroms are employed.

In other preferred applications, non-porous microparticles are employed for their optical properties, which may be advantageously used when tracking large numbers of microparticles on planar supports, such as a microscope slide. Particularly preferred non-porous microparticles are the glycidial

methacrylate (GMA) beads available from Bangs Laboratories (Carmel, IN). Such microparticles are useful in a variety of sizes and derivatized with a variety of linkage groups for synthesizing tags or tag complements. Preferably, for massively parallel manipulations of tagged microparticles, GMA beads having diameters of about 5 μm diameter are employed.

B. Tag Sequences

The tags of the invention are designed to provide unique tagging sequences for sample species of interest, and for specific hybridization to corresponding tag complements immobilized on one or more solid supports. The sequences of the tags (and tag complements) can be any group of sequences selected by the user, provided that (1) each different tag and tag complement does not significantly cross-hybridize with any other tag or tag complement in the repertoire, under selective hybridization conditions for sorting, (2) each tag and tag complement does not form secondary structure that would prevent specific hybridization with the intended complementary sequence, and (3) each tag can specifically recognize and hybridize to its corresponding tag complement under the same conditions for all tags in the selected tag repertoire. Generally, the number of different tags increases in proportion to the number of different sample species that are to be processed in parallel. Tag sequences may be designed in accordance with any suitable method, such that the desired sequence specificity and sensitivity is achieved.

In a preferred embodiment of the invention, the oligonucleotide tag sequences are selected from a "minimally cross-hybridizing set" of oligonucleotide sequences. Preferably, the sequences of any two oligonucleotide tags of a tag repertoire differ by at least two nucleotides when the oligonucleotides are aligned to achieve maximum sequence identity. In other words, duplex or triplex formation between any tag in a repertoire and any other tag in the repertoire, or a tag complement thereof, results in at least two mismatches. In a more particular embodiment, the tag sequences in a tag repertoire are designed to ensure that duplexes and triplexes cannot form with any other tags or tag complements in the repertoire without forming at least three mismatched nucleotides, and so on. In such embodiments, greater specificity is achieved as the minimum number of mismatches increases, but the total repertoire of tags is smaller. Thus, for tags of a given length, there is a trade-off between the desired specificity and the size of repertoire.

The nucleotide sequences for oligonucleotides of a minimally cross-hybridizing set (repertoire) can be conveniently enumerated by simple computer programs following the procedures described in PCT Publication WO 96/41011 (see especially Fig. 1, the programs provided in Appendices Ia and Ib, and the corresponding discussion in the text) and PCT Publication WO 97/46704 (Appendices I and II), which are incorporated herein by reference. Program minhx of Appendix Ia in WO 96/41011 computes all minimally cross-hybridizing sets having 4-mer subunits composed of three kinds of nucleotides. Program tagN of Appendix Ib (WO 96/41011) enumerates longer oligonucleotides of a minimally cross-hybridizing set. Program 3tagN (WO 97/46704 at Appendix II) can be used to produce

minimally cross-hybridizing sets of double stranded tags for binding single-stranded tag complements. Similar algorithms and computer programs are readily written for listing oligonucleotides of minimally cross-hybridizing sets for any embodiment of the invention. Table I below provides guidance as to the size of sets of minimally cross-hybridizing oligonucleotides for the indicated lengths and number of nucleotide differences, wherein the above-mentioned computer programs were used to generate the numbers shown.

Table I

Oligonucleotide Subunit Length	Nucleotide Difference between Oligonucleotides of Minimally Cross-Hybridizing Set	Maximal Size of Minimally Cross-Hybridizing Set	Size of Repertoire with Four Subunits	Size of Repertoire with Five Subunits
4	3	9	6561	5.90×10^4
6	3	27	5.3×10^5	1.43×10^7
7	4	27	5.3×10^5	1.43×10^7
7	5	8	4096	3.28×10^4
8	3	190	1.30×10^9	2.48×10^{11}
8	4	62	1.48×10^7	9.16×10^8
8	5	18	1.05×10^5	1.89×10^6
9	5	39	2.31×10^6	9.02×10^7
10	5	332	1.21×10^{10}	
10	6	28	6.15×10^5	1.72×10^7
11	5	187		
18	6	≈ 25000		
18	12	24		

For some embodiments of the invention, where extremely large repertoires of tags are not required, oligonucleotide tags of a minimally cross-hybridizing set may be separately synthesized. Sets containing several hundred to several thousands, or even several tens of thousands, of oligonucleotides may be synthesized directly by a variety of parallel synthesis approaches, e.g. as disclosed in Frank et al., U.S. patent 4,689,405; Frank et al., Nucleic Acids Research, 11: 4365-4377 (1983); Matson et al., Anal. Biochem., 224: 110-116 (1995); Fodor et al., International application PCT/US93/04145 (WO 93/22684); Pease et al., Proc. Natl. Acad. Sci., 91: 5022-5026 (1994); Southern et al., J. Biotechnology, 35: 217-227 (1994), Brennan, International application PCT/US94/05896 (WO 94/27719); Lashkari et al., Proc. Natl. Acad. Sci., 92: 7912-7915 (1995); or the like.

Preferably, oligonucleotide tags of the invention are synthesized combinatorially out of subunits (also referred to as "words") that are three to nine, and preferably three to six, nucleotides in length and are selected from the same minimally cross-hybridizing set. For oligonucleotides in this range, the members of such sets may be enumerated by computer programs based on the algorithm of Fig. 1 from

WO 96/41011.

Preferably, minimally cross-hybridizing sets comprise subunits that make approximately equivalent contributions to duplex (or triplex) stability as every other subunit in the set. In this way, the stability of perfectly matched duplexes between every subunit and its complement is approximately equal. Guidance for selecting such sets is provided by published techniques for selecting optimal PCR primers and calculating duplex stabilities, e.g. Rychlik et al., *Nucleic Acids Research*, 17: 8543-8551 (1989) and 18: 6409-6412 (1990); Breslauer et al., *Proc. Natl. Acad. Sci.*, 83: 3746-3750 (1986); Wetmur, *Crit. Rev. Biochem. Mol. Biol.*, 26: 227-259 (1991); and the like. For shorter tags, e.g. about 30 nucleotides or less, the algorithm described by Rychlik and Wetmur is preferred, and for longer tags, e.g. about 30-35 nucleotides or greater, an algorithm disclosed by Suggs et al., pages 683-693 in Brown, editor, *ICN-UCLA Symp. Dev. Biol.*, Vol. 23 (Academic Press, New York, 1981) may be conveniently employed. Clearly, there are many approaches available to one skilled in the art for designing sets of minimally cross-hybridizing subunits within the scope of the invention. For example, to minimize the affects of different base-stacking energies of terminal nucleotides when subunits are assembled, subunits may be provided that have the same terminal nucleotides. In this way, when subunits are linked, the sum of the base-stacking energies of all the adjoining terminal nucleotides will be the same, thereby reducing or eliminating variability in tag melting temperatures.

A "word" of terminal nucleotides, shown in *italics* with underlining below, may also be added to each end of a tag so that a perfect match is always formed between it and a similar terminal "word" on any other tag complement. Such an augmented tag would have the form:

<u><i>W</i></u>	W ₁	W ₂	...	W _{k-1}	W _k	<u><i>W</i></u>
<u><i>W'</i></u>	W ₁ '	W ₂ '	...	W _{k-1} '	W _k '	<u><i>W'</i></u>

where the primed W's indicate complements. With ends of tags always forming perfectly matched duplexes, all mismatched subunits (words) will cause internal mismatches, thereby reducing the stability of tag-complement duplexes that otherwise would have mismatched words at their ends. It is well known that duplexes with internal mismatches are significantly less stable than duplexes with the same mismatch at a terminus.

A preferred embodiment of minimally cross-hybridizing sets are those whose words are made up of three of the four natural nucleotides. The absence of one type of nucleotide in the oligonucleotide tags permits the tags to be converted from double- to single-stranded form, if desired, using the 5'→3' exonuclease activity of a DNA polymerase to remove the tag complement strand (stripping reaction). The following is an exemplary minimally cross-hybridizing set of words each comprising four nucleotides selected from the group consisting of A, G, and T:

Table II

Word:	W1	W2	W3	W4
Sequence:	GATT	TGAT	TAGA	TTTG
Word:	W5	W6	W7	W8
Sequence:	GTAA	AGTA	ATGT	AAAG

In this set, each member would form a duplex having three mismatched bases with the complement of every other member.

- Further exemplary minimally cross-hybridizing sets are listed below in Table III. Clearly, additional sets can be generated by substituting different groups of nucleotides, or by using subsets of known minimally cross-hybridizing sets.

Table IIIExemplary Minimally Cross-Hybridizing Sets of 4-mer Subunits (Words)

<u>Set 1</u>	<u>Set 2</u>	<u>Set 3</u>	<u>Set 4</u>	<u>Set 5</u>	<u>Set 6</u>
CATT	ACCC	AAAC	AAAG	AACA	AACG
CTAA	AGGG	ACCA	ACCA	ACAC	ACAA
TCAT	CACG	AGGG	AGGC	AGGG	AGGC
ACTA	CCGA	CACG	CACC	CAAG	CAAC
TACA	CGAC	CCGC	CCGG	CCGC	CCGG
TTTC	GAGC	CGAA	CGAA	CGCA	CGCA
ATCT	GCAG	GAGA	GAGA	GAGA	GAGA
AAAC	GGCA	GCAG	GCAC	GCCG	GCCC
	AAAA	GGCC	GGCG	GGAC	GGAG
<u>Set 7</u>	<u>Set 8</u>	<u>Set 9</u>	<u>Set 10</u>	<u>Set 11</u>	<u>Set 12</u>
AAGA	AAGC	AAGG	ACAG	ACCG	ACGA
ACAC	ACAA	ACAA	AACA	AAAA	AAAC
AGCG	AGCG	AGCC	AGGC	AGGC	AGCG
CAAG	CAAG	CAAC	CAAC	CACC	CACA
CCCA	CCCC	CCCG	CCGA	CCGA	CCAG
CGGC	CGGA	CGGA	CGCG	CGAG	CGGC
GACC	GACA	GACA	GAGG	GAGG	GAGG
GCGG	GCGG	GCGC	GCCC	GCAC	GCCC
GGAA	GGAC	GGAG	GGAA	GGCA	GGAA

C. Tag Synthesis

Oligonucleotide tag complements for use in the invention are conveniently synthesized on an automated DNA synthesizer, e.g. an Applied Biosystems model 392 or 394 DNA/RNA Synthesizer (Perkin-Elmer Applied Biosystems, Foster City, CA), or a "GENE ASSEMBLER PLUS" (Pharmacia), using standard chemistries, preferably phosphoramidite chemistry, e.g., as disclosed in the following references: Beaucage and Iyer, *Tetrahedron*, 48: 2223-2311 (1992); Molko et al., U.S. patent 4,980,460; Koster et al., U.S. patent 4,725,677; Caruthers et al., U.S. patents 4,415,732; 4,458,066; and 4,973,679; M.J. Gait (Ed.) in *Oligonucleotide Synthesis, a Practical Approach*, IRL Press, Oxford,

England (1990); and the like.

When microparticles are used as supports, repertoires of tag complements may be generated by word-wise synthesis via "split and mix" techniques, e.g. as disclosed in Shortle et al., International patent application PCT/US93/03418 (WO 93/21203) or Lytle et al., Biotechniques, 19: 274-280 (1995). Briefly, the basic unit of the synthesis is a subunit ("word") of the tag sequence. Preferably, phosphoramidite chemistry is used and 3' phosphoramidite oligonucleotides are prepared for each word in a minimally cross-hybridizing set, e.g. for the set first listed above, there would be eight 3'-phosphoramidite tetramers. Synthesis proceeds as disclosed by Shortle et al or in direct analogy with the techniques employed to generate diverse oligonucleotide libraries using nucleosidic monomers, e.g. as disclosed in Telenius et al., Genomics, 13: 718-725 (1992); Welsh et al., Nucleic Acids Research, 19: 5275-5279 (1991); Grothues et al., Nucleic Acids Research, 21: 1321-1322 (1993); Hartley, European patent application no. 90304496.4; Lam et al., Nature, 354: 82-84 (1991); Zuckerman et al., Int. J. Pept. Protein Research, 40: 498-507 (1992); and the like. Generally, these techniques simply call for the application of mixtures of the activated monomers (or polymer words) to the growing oligonucleotide during the coupling steps.

Preferably, tag complements are synthesized on a DNA synthesizer having a number of synthesis chambers which is greater than or equal to the number of different kinds of words used in the construction of the tags. That is, preferably there is a synthesis chamber corresponding to each type of word. In this embodiment, words are added nucleotide-by-nucleotide, such that if a word consists of five nucleotides there are five monomer couplings in each synthesis chamber. After a word is completely synthesized, the synthesis supports are removed from the chambers, mixed, and redistributed back to the chambers for the next cycle of word addition. This latter embodiment takes advantage of the high coupling yields of monomer addition, e.g. in phosphoramidite chemistries (e.g., see Example 1).

The tag and tag-complement sequences of the invention preferably have a length range from 12 to 60 nucleotides or basepairs. Preferably, the tag sequences range in length from 18 to 40 nucleotides or basepairs. More preferably, the tag sequences have lengths from 25 to 40 nucleotides or basepairs. In terms of preferred and more preferred numbers of words, these ranges may be expressed as follows:

Table IV

Numbers of Subunits (Words) in Preferred Tag Embodiments

Monomers in Subunit	Nucleotides in Oligonucleotide Tag		
	(12-60)	(18-40)	(25-40)
3	4-20 subunits	6-13 subunits	8-13 subunits
4	3-15 subunits	4-10 subunits	6-10 subunits
5	2-12 subunits	3-8 subunits	5-8 subunits
6	2-10 subunits	3-6 subunits	4-6 subunits

Most preferably, oligonucleotide tags are single-stranded, and specific hybridization occurs via Watson-Crick pairing with a tag complement.

Preferably, repertoires of tags and/or tag complements of the invention contain at least 100 members; more preferably at least 1000 members; and most preferably at least 10,000 members.

In embodiments where specific hybridization occurs via triplex formation, coding of tag sequences follows the same principles as for duplex-forming tags; however, there are further constraints on the selection of word sequences. Generally, third strand association via Hoogsteen type of binding is most stable along homopyrimidine-homopurine tracks in a double stranded target. Usually, base triplets form in T-A*T or C-G*C motifs (where "-" indicates Watson-Crick pairing and "*" indicates Hoogsteen type of binding); however, other motifs are also possible. For example, Hoogsteen base pairing permits parallel and antiparallel orientations between the third strand (the Hoogsteen strand) and the purine-rich strand of the duplex to which the third strand binds, depending on conditions and the composition of the strands. There is extensive guidance in the literature for selecting appropriate sequences, orientation, conditions, nucleoside type (e.g. whether ribose or deoxyribose nucleosides are employed), base modifications (e.g. methylated cytosine, and the like in order to maximize, or otherwise regulate, triplex stability as desired in particular embodiments, e.g. Roberts et al., Proc. Natl. Acad. Sci., 88: 9397-9401 (1991); Roberts et al., Science, 258: 1463-1466 (1992); Roberts et al., Proc. Natl. Acad. Sci., 93: 4320-4325 (1996); Distefano et al., Proc. Natl. Acad. Sci., 90: 1179-1183 (1993); Mergny et al., Biochemistry, 30: 9791-9798 (1991); Cheng et al., J. Am. Chem. Soc., 114: 4465-4474 (1992); Beal and Dervan, Nucleic Acids Research, 20: 2773-2776 (1992); Beal and Dervan, J. Am. Chem. Soc., 114: 4976-4982 (1992); Giovannangeli et al., Proc. Natl. Acad. Sci., 89: 8631-8635 (1992); Moser and Dervan, Science, 238: 645-650 (1987); McShan et al., J. Biol. Chem., 267: 5712-5721 (1992); Yoon et al., Proc. Natl. Acad. Sci., 89: 3840-3844 (1992); Blume et al., Nucleic Acids Research, 20: 1777-1784 (1992); Thuong and Helenc, Angew. Chem. Int. Ed. Engl. 32: 666-690 (1993); Escude et al., Proc. Natl. Acad. Sci., 93: 4365-4369 (1996); and the like.

Conditions for annealing single-stranded or duplex tags to their single-stranded or duplex complements are well known, e.g. Ji et al., Anal. Chem. 65: 1323-1328 (1993); Cantor et al., U.S. patent 5,482,836; and the like. Use of triplex tags has the advantage of not requiring a "stripping" reaction with polymerase to expose the tag for annealing to its complement, if the tag was initially prepared in double-stranded form.

Preferably, oligonucleotide tags of the invention employing triplex hybridization are double stranded DNA and the corresponding tag complements are single stranded. More preferably, 5-methylcytosine is used in place of cytosine in the tag complements in order to broaden the range of pH stability of the triplex formed between a tag and its complement. Preferred conditions for forming triplexes are fully disclosed in the above references. Briefly, hybridization takes place in concentrated

salt solution, e.g. 1.0 M NaCl, 1.0 M potassium acetate, or the like, at pH below 5.5 (or 6.5 if 5-methylcytosine is employed). Hybridization temperature depends on the length and composition of the tag; however, for an 18-20-mer tag or longer, hybridization at room temperature is adequate. Washes may be conducted with less concentrated salt solutions, e.g. 10 mM sodium acetate, 100 mM MgCl₂, pH 5.8, at room temperature. Tags may be eluted from their tag complements by incubation in a similar salt solution at pH 9.0.

Minimally cross-hybridizing sets of oligonucleotide tags that form triplexes may be generated by the computer program 3tagN in Appendix II of WO 97/46704, or similar programs. An exemplary set of double stranded 8-mer words is given below in capital letters with the corresponding complements in small letters. Each such word differs from each of the other words in the set by three base pairs.

Table V

Exemplary Minimally Cross-Hybridizing Set of Double Stranded 8-mer Tags

5' -AAGGAGAG	5' -AAAGGGGA	5' -AGAGAAGA	5' -AGGGGGGG
3' -TTCTCTC	3' -TTCCCTCT	3' -TCTCTCT	3' -TCCCCCCC
3' -ttctctc	3' -tttcccct	3' -tctctct	3' -tcccccc
5' -AAAAA	5' -AAGAGAGA	5' -AGGAAAAG	5' -GAAAGGAG
3' -TTTTTTT	3' -TTCTCTCT	3' -TCCTTTTC	3' -CTTCTCTC
3' -ttttttt	3' -ttctctct	3' -tccttttc	3' -cttctctc
5' -AAAAAGGG	5' -AGAAGAGG	5' -AGGAAGGA	5' -GAAGAAGG
3' -TTTTTCCC	3' -TCTTCTCC	3' -TCCTTCCT	3' -CTTCTTCC
3' -tttttccc	3' -tcttctcc	3' -tccttctc	3' -cttcttcc
5' -AAAGGAAG	5' -AGAAGGAA	5' -AGGGGAAA	5' -GAAGAGAA
3' -TTTCCTTC	3' -TCTTCCTT	3' -TCCCCTTT	3' -CTTCTCTT
3' -tttccttc	3' -tcttcctt	3' -tccccttt	3' -cttctctt

Table VI

Repertoire Size of Various Double Stranded Tags That Form Triplexes with Their Tag Complements

Oligonucleotide Word Length	Nucleotide Difference between Oligonucleotides of Minimally Cross-Hybridizing Set	Maximal Size of Minimally Cross-Hybridizing Set	Size of Repertoire with Four Words	Size of Repertoire with Five Words
4	2	8	4096	3.2×10^4
6	3	8	4096	3.2×10^4
8	3	16	6.5×10^4	1.05×10^6
10	5	8	4096	
15	5	92		
20	6	765		
20	8	92		
20	10	22		

Preferably, repertoires of double stranded oligonucleotide tags of the invention contain at least 10 members; more preferably, repertoires of such tags contain at least 100 members. Preferably, words are between 4 and 8 nucleotides in length for combinatorially synthesized double stranded oligonucleotide tags, and tag sequences for triplex formation are from 12 to 60 base pairs in length. More preferably, the tag sequences are from 18 to 40 base pairs in length.

D. Solid Phase Linkers

During synthesis, tag complements of the invention are bound to one or more solid phase supports by first and second types of linking moieties, such that (1) both types of linking moieties remain intact (uncleaved) during tag complement synthesis, and (2) a first type of linking moiety can be cleaved to release the synthesized oligonucleotide under conditions in which the second linking moiety (or moieties) is/are not cleaved. Preferably, the cleavable linkage is a chemically cleavable linkage, i.e., suitable for selective cleavage without using a cleaving enzyme.

A large number of linking chemistries, and their cleavage properties, are known. Exemplary cleavable linking moieties, which are not intended to be limiting, include base-labile, acid-labile, photolabile, reducible, and enzyme-labile moieties.

Base-labile linkages include esters ($-C(O)O-$), thioesters ($-C(O)S-$), and 2-oxyethyl sulfones ($-OCH_2CH_2-S(=O)_2R$), for example. Such linkages can be cleaved under basic conditions, typically using a $pH \geq 8.0$, preferably $pH \geq 9.0$, for a suitable time, and optionally including a suitable nucleophile, such as ammonia, to increase pH and/or to promote cleavage by nucleophilic attack. For example, a di(2-oxyethyl)sulfone linking moiety can be cleaved by reaction with ammonia (28-30% in water) under mild conditions (55°C for 12-15 hours) without significant harm to the oligonucleotide (Example 1). Synthesis of a support containing a mixture of succinate ester (cleavable) and succinamide (non-cleavable) linking moieties is described in Example 3.

Acid-labile linkages include esters ($-C(O)O-$), thioesters ($-C(O)S-$), ketals ($O-C(R_1R_2)-O-$), hemiketals ($O-CHR-O-$), and phosphoramidates ($-OP(=O)(O^-)N-$) for example. For example, a phosphoramidate linkage can be introduced to a support by methods described in Hirschbein et al. (PCT App. PCT/US96/10418, Pub. No. WO 97/31009) or Gryaznov et al. (U.S. Patent No. 5,599,922), and can be cleaved by treatment with 0.8% trifluoroacetic acid in dichloromethane for 40 minutes at room temperature (see also Gryaznov et al., Nucleic Acids Res. 20:3403-3409 (1992)).

Exemplary photolabile linkers include 2-nitrobenzyl esters, such as described by D.J. Yoo et al., Org. Chem. 60:3358-3364 (1995); D.L. McMinn et al., Tetrahedron 52:3827-3840 (1996); and U.S. Patent No. 5,430,136 to Urdea.

Reducible linkers are exemplified by disulfide linking groups which are readily reduced with 2-mercaptoethanol or dithiothreitol, for example (Gryaznov et al., Nucleic Acids Res. 21:1403-1408 (1993); U.S. Patent No. 5,118,605 to Urdea).

Enzyme-labile groups include any linking moiety that can be cleaved by an enzyme. Exemplary

linking moieties include ester groups (-C(O)-O-), peptide groups (-NH-C(O)-), thioesters (-C(O)-S), and polynucleotide sequences that contain endonuclease restriction sites (e.g., U.S. Patent No. 4,775,619 to Urdea). In one preferred embodiment, the linking moiety is an oligopeptide containing an amino acid residue that is recognized by a specific protease, e.g., lysine-X or arginine-X (trypsin); aspartate-X (Staphylococcus aureus V8 protease); or tyrosine-X, tryptophan-X, phenylalanine-X, leucine-X, or methionine-X (α -chymotrypsin); where X represents the next residue in the N \rightarrow C direction of the peptide. If cleavage of the oligopeptide linking group yields an oligonucleotide-peptide conjugate, the peptide portion can be removed, if desired, using pronase or other suitable protease, or the oligonucleotide can include an endonuclease restriction site that is positioned to permit selective removal of the peptide portion from the oligonucleotide.

Other chemical linkages are also contemplated, such as oligopeptides containing methionine, which are chemically cleavable using cyanogen bromide under acidic conditions. Additional references which describe cleavable linking moieties include Monforte et al., International App. No. PCT/US96/06116 (WO 96/37630), Urdea (U.S. Patent 5,380,833), Wong, S.S., Chemistry of Protein Conjugation and Cross-Linking, CRC Press Boca Raton, FL, 1991 (particularly pp. 63-67) and Allen, G., Sequencing of Proteins and Peptides, Elsevier Science Pub. B.V., New York, 1983 (particularly Chapter 3), which are incorporated herein by reference.

Many stable linking moieties are also known that are generally resistant to the cleavage conditions mentioned above. Exemplary stable, "non-cleavable" moieties include ethers and polyethers, polyamines, phosphoramidites, phosphoramidates, and the like. These moieties are resistant under most acidic and basic conditions, in contrast to some of the groups noted above, and are therefore particularly convenient choices for the non-cleavable linkages used in the invention.

Exemplary linkers for attaching and/or synthesizing tags on microparticle surfaces are described in Pon et al., *Biotechniques*, 6:768-775 (1988); Webb, U.S. patent 4,659,774; Barany et al., International patent application PCT/US91/06103 (WO 92/04384); Brown et al., *J. Chem. Soc. Commun.*, 1989: 891-893; Damha et al., *Nucleic Acids Research*, 18: 3813-3821 (1990); Beattie et al., *Clin. Chem.*, 39: 719-722 (1993); Maskos and Southern, *Nucleic Acids Research*, 20: 1679-1684 (1992); and the like.

III. Repertoire Synthesis Method

The present invention provides a method for synthesizing a repertoire of oligonucleotide tags and a corresponding repertoire of tag complements, such that synthesis fidelity and yields of desired tags are improved, and problems caused by failure sequences are reduced, relative to previous methods in which tags and tag complements were synthesized separately.

In one embodiment, the method entails (1) synthesizing a plurality of different-sequence oligonucleotide populations immobilized on one or more solid phase supports, wherein each population comprises a plurality of same-sequence oligonucleotides, and the oligonucleotides in each population

5 comprise a tag complement sequence that is distinct relative to the tag complement sequences in the other populations, (2) cleaving a fraction of each oligonucleotide population from the one or more supports, and (3) inserting the cleaved oligonucleotides into a plurality of cloning vectors to form a tag-vector library. Such a process is illustrated in Fig. 2, where tag-vector construct $\underline{1}$, containing a cleaved tag complement

10 sequence T_n , illustrates a member of a tag-vector library.

The solid phase support(s) for use in the invention can be prepared by any suitable method in light of the description in section II above. As noted above, the linking moieties that link the tag complements to the support comprise a mixture of at least two different linking moieties comprising a first, cleavable

15 linking moiety and a second, non-cleavable linking moiety. Both the cleavable and non-cleavable linking moieties are selected to withstand the oligonucleotide synthesis protocol that is used to build the tag complement sequences on the support. The non-cleavable linking moiety must also be able to withstand conditions used later to hybridize tagged molecules to the support-bound tag complements.

The ratio of cleavable:non-cleavable linking moieties on the support is selected to ensure that (1) a sufficient amount of the tag complement repertoire synthesized on the support can be cleaved from the support, for preparing a complementary tag repertoire, (2) the cleaved oligonucleotides are clonable or can

25 readily be made clonable, and (3) a sufficient amount of tag complements remains on the support for capturing tagged molecules when the support is used for sorting. Preferably, the cleavable linking moieties constitute less than 50%, and more preferably, from about 10% to about 30% of total bound tag complements. It is also preferred that a selected fraction of each population of synthesized

30 oligonucleotides is bound to the support or supports via base-cleavable linkages.

A large number of suitably reactive supports are known, as discussed above, for attaching the desired linking moieties. For example, hydroxyl or amino-derivatized supports are commercially available or can be prepared from readily available materials, as discussed above, which are suitable for attaching selected

35 linker groups.

25 The cleavable and non-cleavable linking groups can be attached to the support sequentially or simultaneously. Preferably, the linking moieties can be introduced onto a solid phase support by simultaneously reacting a mixture of cleavable and non-cleavable linkers with complementary reactive groups on the support. Thus, the relative proportions of cleavable and non-cleavable moieties on the support can be controlled by appropriate selection of the linker ratio for the derivatization reaction, taking

40 into account the relative reactivities of the linkers with respect to the complementary reactive groups on the solid support. For example, when the cleavable and non-cleavable linkers are equally reactive toward the support, a cleavable:non-cleavable linker ratio of 10:90 can be used to produce a derivatized support in which 10% of the attached tag complements are cleavable from the support. Similarly, a ratio of 30:70 can be used to produce a derivatized support in which 30% of the tag complements are cleavable. If necessary,

45 the relative proportion of a less reactive linker can be increased to offset a higher reactivity of the other linker-type.

50

For example, in the protocol described in Example 1, glycidal methacrylate/ethylene dimethacrylate (95/5) crosslinked beads derivatized with ethylene diamine were reacted simultaneously with a 10:90 molar ratio of cleavable:non-cleavable linkers, by standard phosphoramidite reaction chemistry. By this reaction, both linkers are attached to amino groups on the support to form phosphoramidite linkages which can later be oxidized to form stable phosphoramidate groups (Figure 1). The cleavable linker, which can be introduced on to the support as 2-[2-(4,4'-dimethoxytrityloxy)-ethylsulfonyl]ethyl-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite, contains a di(2-oxyethyl) sulfone moiety which is stable to acidic and oxidative conditions and remains intact during oligonucleotide synthesis, but is susceptible to base-catalyzed cleavage as shown in Figure 1. The non-cleavable linker in Fig. 1, which can be added to the support as 9-O-dimethoxytrityl-triethyleneglycol, 1-[(2-cyanoethyl)-N,N-diisopropyl]-phosphoramidite, comprises a polyethylene oxide linker that is stable to oligonucleotide synthesis conditions and to the basic conditions that can be used to cleave the cleavable linking moiety.

Oligonucleotides containing the tag complements are added to the linker-derivatized support using any appropriate reaction conditions. A wide variety of synthesis strategies have been developed in the art, and have been described (e.g., Gait, 1990 (supra), and other synthesis references cited above). Currently, the solid-phase phosphoramidite method is preferred, since it provides coupling yields of about 99% or greater. Preferably, synthesis is automated using any of a variety of available instruments and reagents to provide efficient synthesis.

To facilitate the preparation of a tag repertoire that is complementary to the tag complements, the immobilized tag complement oligonucleotides preferably include first and second primer segments that flank the tag complement sequence in each oligonucleotide. Thus, following attachment of the linkers to the support, a first primer sequence is preferably added to the linker, typically by sequential addition of the appropriate monomers to the linkers. In the protocol described in Example 1, a primer segment having the sequence 5'-TCCTTAATTAAGTGGTCTCACTGTCGCA-3' (SEQ ID NO:1) is added by sequential monomer addition in the 3' to 5' direction using phosphoramidite-phosphotriester chemistry. Alternatively, a primer segment can be synthesized separately and can be attached to the linker in a single coupling reaction. Preferably, the linker and any attached primer sequence together provide a spacer moiety containing stretch of at least 10 chain atoms, to help separate the tag complement segment (discussed immediately below) from the surface of the support and from other tag complements on the support. Preferably, the spacer (including an optional primer-binding sequence) has a length of from 10 to 30 nucleotides. The presence of a spacer moiety is particularly useful to ensure that the tag complements will be readily accessible to hybridization with complementary tag sequences for sorting.

The tag complement sequence in each oligonucleotide can be added by sequential addition of monomers or blocks of monomers, or by simultaneous attachment of a separately synthesized repertoire of tag complements, with sequential addition of monomers being preferred. Repertoires can be formed on a

planar array by photolithographic or robotic dispensing methods as are known in the art (supra). For
repertoires formed on beads or particles, tag complement sequences are preferably formed combinatorially
using a split and mix approach, such as described by Brenner in PCT Publication No. WO 96/41011. In
brief, a plurality of different, minimally cross-hybridizing oligonucleotide "word" sequences are selected,
which are designed to ensure that the synthesized tag complements will only be able to hybridize to their
corresponding complementary tags under selected hybridization conditions, i.e., so that the levels of any
incorrectly hybridized tags and tag complements are insignificant.

In the protocol described in Example 1, each tag complement sequence consists of a linear string of
eight "words", each selected from the same set of eight tetrameric words. The primer-derivatized beads are
divided into eight aliquots which are loaded into eight separate synthesis columns on an automated
synthesizer. In each column, a different word selected from the eight possible words is added to the beads
by sequential addition of appropriate monomers. After synthesis of the first word in each column is
complete, the beads from the eight columns are combined and gently mixed together to homogeneity.
After mixing, the bead mixture is divided again into equal aliquots which are loaded into the eight columns
for another cycle of word addition. A total of eight cycles of word addition are performed, to produce
beads with a total of 8^8 ($\approx 1.7 \times 10^7$) different possible tag complement sequences. The split and mix
protocol ensures that each bead contains a substantially uniform population of same-sequence
oligonucleotides, i.e., the oligonucleotides on a particular bead have substantially the same sequences.

If necessary, the sequences of immobilized tag complements can be determined directly on the solid
phase support by any known sequencing method. Preferably, the tag complements contain a universal
primer-binding sequence on the 3'-side of the tag complement sequence, so that the tag complements can
be sequenced by the Sanger dideoxy sequencing method, by annealing and extending a complementary
sequencing primer. However, usually it is not necessary to know the sequences of the immobilized tag
complements.

Following addition of the tag complement sequence, additional nucleotide residues can be appended
to incorporate a second primer sequence, one or more endonuclease restriction sites, and/or any other
desired features. For example, in the protocol of Example 1, a hexameric block of GGGCCC is appended
to the tag complement to (1) help anchor the tag complement to its corresponding complementary tag
during hybridization, (2) define the end of the tag complement segment, and (3) introduce a BspI20I
restriction site for subsequent ligation to a vector. This is followed by addition of a second primer
sequence (primer 2) for optional amplification as discussed further below.

Thus, in a preferred embodiment, the immobilized oligonucleotides that contain the tag complement
sequences include the following features:

[support] - [linking moiety] - [spacer] - [tag complement] - [terminal segment]

wherein the linking moiety is either cleavable or non-cleavable as discussed above, the spacer segment

(preferably having a length of 10 to 30 nucleotides) optionally contains (1) an endonuclease restriction site and/or (2) a universal primer-binding sequence, the tag complement segment (preferably having a length of 12 to 60, 18 to 40, or 25 to 40 nucleotides) has the features discussed above, and the terminal segment (preferably having a length of 0-40 nucleotides, or 10 to 30 nucleotides) optionally contains (1) an endonuclease restriction site which may be the same or different from the first restriction site and (2) a universal primer sequence which may be the same or different from the complement of any primer-binding sequence in the spacer. In one preferred embodiment, the tag complement sequence in each oligonucleotide is flanked by first and second endonuclease restriction sites which may be the same or different, to facilitate subsequent ligation into a selected vector.

After oligonucleotide synthesis is complete, the oligonucleotides are deprotected if necessary, and a portion of the tag complement repertoire is cleaved from the support(s) using appropriate reaction conditions to selectively cleave only the cleavable linking moieties, while leaving the non-cleavable linking moieties intact.

Conveniently, the cleavage step and any deprotection steps are performed simultaneously using a single reagent. For example, if the cleavable linking moiety and one or more protecting groups are base-labile, then the support can be treated with base to remove the protecting groups and cleave the cleavable oligonucleotides from the support. Of course, the deprotection and cleavage steps can also be performed separately.

The cleaved oligonucleotide mixture can be inserted directly into a selected cloning vector, as discussed further below. However, the mixture is preferably purified to remove failure sequences and other extraneous materials, using any convenient method. For example, the mixture can be rapidly and conveniently purified by HPLC by ion exchange or reverse-phase chromatography by known methods. Electrophoretic separations can also be used. For reverse-phase chromatography, the synthesized oligonucleotides preferably contain a hydrophobic group, such as trityl or dimethoxytrityl (DMT), to facilitate preferential adsorption of tritylated oligonucleotides on the adsorbent, while non-tritylated sequences (arising from failed coupling steps) are substantially unretained by the column. Typically, the desired oligonucleotide mixture elutes (or migrates) as a broad peak since a vast spectrum of sequences with different G/C content and distribution are present. The mixture may be further purified by ethanol extraction or the like, and the resultant mixture can be stored dry or in a stable storage medium, preferably below 0°C. The integrity of the sequences of the oligonucleotides can be evaluated by randomly sequencing individual members of the mixture (usually after the mixture has been inserted into a cloning vector).

For subsequent attachment to sample polynucleotides of interest, the cleaved oligonucleotides are preferably inserted into one or more cloning vectors to form a tag vector library. Any type of replicable vector can be used, such as a plasmid, phagemid, cosmid, or the like, which can be propagated in an appropriate host. The vector can be single-stranded or double-stranded. A variety of suitable vectors are

5 available from commercial sources (e.g., New England Biolabs, Clontech, GibcoBRL, etc.) or have been described in the literature. The vector will generally contain one or more restriction sites for inserting foreign DNA, at least one selection marker (e.g., ampicillin resistance), optionally a universal primer sequence upstream of the insertion site (e.g., for sequencing the insert), and any necessary components for
10 propagating the vector in an appropriate host. Preferably, the vector includes a first restriction site for inserting an oligonucleotide tag, and a second restriction site immediately adjacent the first site, for inserting a sample fragment in close proximity to a tag. Alternatively, the restriction site for inserting the sample fragment can be introduced into the vector via the tag oligonucleotide, which contains an
15 endonuclease site immediately adjacent to the tag segment.

10 For insertion into a double-stranded vector, the cleaved oligonucleotides are preferably converted to double-stranded form by annealing a complementary primer to a universal 3'-primer segment in the oligonucleotides and extending the primer by any suitable means. The double stranded product contains a tag sequence that is perfectly base-paired with a corresponding tag complement sequence. Typically, the annealed primer is extended in the 3' direction using a DNA polymerase in the presence of a mixture of
15 dNTPs. To increase the quantity of double stranded oligonucleotide for insertion into the vector, the oligonucleotide mixture may be amplified by polymerase chain reaction using a pair of primers that anneal to primer-binding sequences that flank the tag complement sequences, until the desired amount of double-stranded product is obtained.

20 The double-stranded tag oligonucleotide mixture can be inserted into a vector by standard ligation techniques, e.g., by blunt end or sticky end ligation. Typically, the vector and oligonucleotide mixture are each treated separately with one or more restriction enzymes to produce products that have cohesive ends. Preferably, the vector and oligo mixture are each treated separately with two different restriction enzymes to produce products having two different sticky ends, to help reduce religation of the vector without
35 incorporating an insert. The cleaved vector can also be treated with calf intestinal phosphatase to inhibit self-ligation of vector without insert. For example, in Example 2D, the oligonucleotide mixture and vector are each treated with *PacI* and *BspI201*. The larger fragment from the cleaved vector is treated with calf intestinal phosphatase and then is reacted with the restricted oligonucleotide mixture in the presence of a
40 ligase, to form a mixture of tag vectors.

The ligation product can then be used to transform a suitable host to create a tag-vector library.

30 The transformants are cultured until the desired number of transformants have been collected. Generally, the number of transformants should exceed the complexity of the tag repertoire to ensure sampling of a high proportion of the members of the repertoire. Preferably, the amount of transformants are sufficient to ensure the presence of at least 90% of the repertoire in the tag-vector library, more preferably at least 95%, and more preferably greater than 99%.

35 Tag-vector libraries of the invention are useful for simultaneously and uniquely tagging large numbers of sample oligonucleotide fragments, so that the tagged oligonucleotides can be sorted onto an

array of tag complements for further processing or analysis. Thus, the tag-vectors can be used to form a library of tagged polynucleotide fragments, by combining a tag-vector library with a mixture of different polynucleotide fragments under ligation conditions effective to insert the different fragments at a site adjacent to a tag-sequence in each vector, so that each sample fragment (S_n in Fig. 2) becomes associated with a different tag (T_n). One member of such a tag-vector library is represented by construct 2 in Fig. 2. Preferably, the complexity of the tag-vector library exceeds the complexity of the sample, to help reduce the possibility of the same tag becoming associated with two or more different sample fragments.

For example, in Example 2D, the tag-vector library pBP9 was digested with BbsI and BamHI to create a large vector fragment having a tag sequence adjacent to the BbsI site (within 20 nucleotides). The vector fragment was treated with phosphatase to remove 5'-phosphate groups, and an oligonucleotide sample mixture (cDNA) having BbsI/BamHI sticky ends was inserted by ligation into the vector. The ligation mixture was used to transform *E. coli* host cells, and aliquots comprising approximately 1.6×10^5 clones were used to inoculate liquid cultures in order to expand the library. Plasmid DNA was extracted from these cultures and stored.

Tagged polynucleotides from the tagged-sample oligonucleotides in the library can be processed or analyzed by any desired method. To facilitate detection, the tagged polynucleotides can be amplified by PCR using a universal primer pair for co-amplification, followed by optional purification of the desired products from template and amplification reagents (Example 2E). If the tags are to be used in single-stranded form, for binding single or double-stranded tag complements, the tag strands can be separated from their complementary strands by denaturation and collection of the desired tag strands, e.g., by solid phase capture of biotinylated tag strands on a streptavidin support. Alternatively, the complementary strand can be removed using an exonuclease with 5'→3' or 3'→5' exonuclease activity in the presence of a selected dNTP that is not contained in the tag complement region, so that the exonuclease effectively stops at the end of the tag complement. For example, if the tag sequence contains A, C and T bases, but not G, then the complementary sequence contains T, G and A but not C. Use of an exonuclease in the presence of CTP is effective to remove the complementary sequence until the first C is reached in the complementary sequence.

The tagged oligonucleotides (also referred to as tagged oligonucleotide fragments) are hybridized to the immobilized tag complement repertoire under suitable hybridization conditions as discussed above or as illustrated in Example 2E. If the solid support comprises particles or beads, the particles or beads can be incubated in the presence of the tagged oligonucleotides with constant agitation to facilitate hybridization, followed by a washing step. If only a small proportion of the beads are hybridized with complementary tags, the hybridized beads can be separated from non-hybridized beads by any suitable method, e.g., by FACS (fluorescence activated cell sorting). For this purpose, the tagged polynucleotides preferably include a detectable label, such as a fluorescent label (e.g., via a PCR

primer) to facilitate detection of hybridized tagged polynucleotides.

After hybridization to the immobilized tag complement repertoire, the tagged polynucleotides can be analyzed according to any suitable method. For example, immobilized tagged polynucleotides can be sequenced, e.g., using the immobilized polynucleotide as templates to generate labeled extension products by cycle sequencing, e.g., as taught by Brenner, International App. No. PCT/US95/12678 (WO 96/12039) and International App. No. PCT/US96/03678 (WO 95/27080). Alternatively, hybridized polynucleotides can be denatured from the support and sequenced according to known solution phase methods.

The invention is also useful for sorting different cDNAs onto a solid support, for sequence analysis or quantification. For example, the tags can be used to conduct differential display experiments to characterize changes in transcript levels from different samples, e.g., for characterization of different cell and tissue-types, disease conditions, etc. The invention can also be used for determining the toxicity of various compounds as disclosed in PCT App. No. PCT/US96/16342 (WO 97/13877).

If the tagged molecules are polypeptides, the immobilized polypeptides can be further characterized, e.g., by treatment with target specific antibodies to identify specific polypeptide species. Synthesis of tag-peptide conjugates is described, for example, in WO 96/12014 at page 14.

Additional uses for the tag and tag-complement repertoires of the invention are disclosed, for example, in WO 95/27080; WO 96/12014; WO 96/12039; WO 96/13877; WO 96/41011; and WO 97/46704, which are incorporated herein by reference, including: tracking, identifying, and/or sorting classes or subpopulations of molecules, DNA sequencing, mRNA fingerprinting, etc.

The invention may be further understood in light of the following examples, which are not intended in any way to limit the scope of the invention.

Example 1

Synthesis of Tag Complements

All commercial chemicals were of synthesis quality and were used without further purification. Oligonucleotide syntheses were performed using a GENE ASSEMBLER PLUS-SPECIAL /4 PRIMERS synthesizer (Pharmacia) using 5.6 μ m amino-derivatized polymeric beads (95% glycidyl methacrylate/5% ethylene dimethacrylate derivatized with ethylene diamine, from Bangs Laboratories, Inc., Fishers, Indiana). The beads were estimated to have an amino group density of about 10^7 amino groups per bead. In addition to the 25 μ m polypropylene filters supplied with the synthesis columns from Pharmacia, a GFA glass filter mat (Whatman) was added to the end of each synthesis column to improve retention of the beads. Alternatively, synthesis columns were constructed out of stainless steel tubing (1-5 mm length x 0.75 inch diameter) having screw-cap ends to hold a 2 μ m pore size PEEK filter at each end to retain the beads (such a column with a 5 mm length has a capacity of about 600 mg of beads).

4.8 g of amino-derivatized beads were packed into each of 8 synthesis columns, each containing 600 mg of beads. To form the cleavable linker moieties, 250 mg of 5'-PHOSPHATE-ON reagent (2-[2-(4,4'-dimethoxytrityloxy)-ethylsulfonyl]ethyl-(2-cyano-ethyl)-(N,N-diisopropyl)-phosphoramidite, from Clontech, catalog no. 5210-2) was dissolved in 3.8 mL of anhydrous acetonitrile to give a concentration of 0.1 M. To form the non-cleavable linker moieties, 250 mg of SPACER PHOSPHORAMIDITE (9-O-dimethoxytrityl-triethyleneglycol, 1-[(2-cyanoethyl)-N,N-diisopropyl])-phosphoramidite, from Clontech, catalog no. 5260-3) was separately dissolved in 3.8 mL anhydrous acetonitrile to give a final concentration of 0.1 M. These two solutions were combined in a ratio to provide any desired % cleavability. For example, to achieve 10% cleavability, 1 part PHOSPHATE-ON solution (e.g., 200 μ L) was combined with 9 parts of SPACER PHOSPHORAMIDITE (e.g., 1800 μ L) in a dry bottle, which was then attached to the extra phosphoramidite port on the GENE ASSEMBLER SPECIAL PRIMERS 4 instrument. All transfers were carried out with a syringe, and the bottles were blanketed with argon to minimize exposure to water vapor in air.

Following addition of the linkers (cleavable and non-cleavable) to the beads, the DNA sequence below (primer 1, SEQ ID NO:1) synthesized on the beads in the 3' to 5' direction using the phosphite triester (phosphoramidite) method (M.J. Gait, Editor, Oligonucleotide Synthesis, a Practical Approach, IRL Press, London, UK, 1990, particularly Chapter 3), using the following protected monomers: T (unprotected), A and C (benzoyl), and G (isobutyryl):

5'-TCCTTAATTAAGTGGTCTCACTGTCGCA-3' (primer 1, SEQ ID NO:1)

Next, a different "word" sequence was appended to the primer template sequence in each column by phosphoramidite synthesis, by sequential addition of the appropriate monomers. The sequences of the 8 words were:

- 1) 5'-CTTT
- 2) 5'-TACT
- 3) 5'-ACAT
- 4) 5'-AATC
- 5) 5'-TTAC
- 6) 5'-TCTA
- 7) 5'-ATCA
- 8) 5'-CAAA

Following completion of the first word addition step, the beads were collected from the columns, mixed together, and reloaded into the columns, after which each different "word" sequence was added separately again in the 8 columns by phosphoramidite synthesis as above, followed by bead collection, remixing, and column re-loading. This cycle of adding words and mixing/splitting beads was performed a total of 8 times to create an oligonucleotide library of about 1.7×10^7 ($= 8^8$) different oligonucleotide sequences. After this combinatorial synthesis was complete, the sequence 5'-CCC-3' (trityl-on) was added to the beads, resulting in a mixture of immobilized oligonucleotides having the

following general formula (SEQ ID NO:2)



↑

PacI

Following addition of the CCC segment, a portion of the beads (4.3 g = 90%) was deprotected with saturated aqueous ammonia (2 mL, 28-30% in water) at 55°C for 12 hours. The deprotected beads were then treated with acetic acid for 15 minutes to remove the terminal 5'-trityl group. After the acid was removed, the beads were washed with methanol and concentrated in vacuo. The beads were then ready for hybridization.

The remaining portion of the beads (0.5 g = 10%) were reacted with appropriate phosphoramidite monomers to add the sequence 5'-CCTTAGGG-3' (primer 2, with trityl on, SEQ ID NO:3) followed by deprotection with ammonia (2 mL) at 55°C for 12 hours. The ammonia treatment was also effective to cleave the cleavable linkers to release 10% of the oligonucleotides from the beads. The beads were removed by centrifugation, and the remaining ammonia solution was concentrated by vacuum to half of the original volume. The cleaved oligonucleotides in this mixture had the general formula (SEQ ID NO:4):



↑

PacI

The oligonucleotide mixture was purified by HPLC chromatography using a 150 mm x 4.6 mm PLRP-S column from Polymer Laboratories (100 Angstrom pore size, 8 µm particles) on a Gilson HPLC instrument. A 2-stage solvent gradient was used: Buffer A: 0.2 M triethyl ammonium acetate and 2% acetonitrile in water; Buffer B: 100% acetonitrile; flow rate = 1 mL/min at room temperature; gradient program: 95% A for 1 minute; reduce to 80% A over 5 minutes and hold at 50% A for 5 minutes; return to 95% A over 5 minutes and maintain at 95% A for 10 minutes to re-equilibrate column. The entire, broad trityl-on peak was collected between 18 minutes and 20 minutes. The collected fractions were concentrated in vacuo, treated with glacial acetic acid for 15 minutes to remove the 5'-trityl groups, and concentrated in vacuo to dryness. The residue was dissolved in 300 µL water and transferred to a 1.5 mL microfuge tube. To this was added 100 µL of 4 M NaCl, and the mixture was vortexed. After addition 1 mL ethanol, the sample was vortexed and then chilled -20°C for 20 minutes. The precipitated DNA was centrifuged, and the supernatant was removed. The precipitation procedure was repeated twice more. The final purified mixture was designated BP9.

Example 2

Cloning and Preparation of Tags

A. Plasmid Cloning Vector. A plasmid cloning vector pLCV2 was created from plasmid vector pBC.SK⁺ (Stratagene) as follows, using the following oligonucleotides:

S-723 (SEQ ID NO:5)

5'-CGA GAA AGA GGG ATA AGG CTC GAG CTT AAT TAA GAG TCG ACG AAT TCG
GGC CCG GAT CCT GAC TCT TTC TCC CT-3'

S-724 (SEQ ID NO:6)

5'-CTA GAG GGA GAA AGA GTC AGG ATC CGG GCC CGA ATT CGT CGA CTC TTA
ATT AAG CTC GAG CCT TAT CCC TCT TTC TCG GTA C-3'

S-785 (SEQ ID NO:7)

5'-TCG AGG CAT AAG TCT TCG AAT TCC ATC ACA CTG GGA AGA CAA CGT AG-3'

S-786 (SEQ ID NO:8)

5'-GAT CCT ACG TTG TCT TCC CAG TGT GAT GGA ATT CGA AGA CTT ATG CC-3'

S-960 (SEQ ID NO:9)

5'-TCG ATT AAT TAA CAA GCT TTG GGC CCT CGA GCA TAA GTC TTC TGC AGA
ATT CGG ATC CAT CGA TGG TCA TAG C-3'

S-961 (SEQ ID NO:10)

5'-TGT TTC CTG CCA CAC AAC ATA CGA GCC GGA AGC GGC CGC TCT AGA-3'

S-962 (SEQ ID NO:11)

5'-AGC GTC TAG AGC GGC CGC TTC CGG CTC GTA TGT TGT GTG GCA GGA AAC
AGC TAT GAC CAT C-3'

S-963 (SEQ ID NO:12)

5'-GAT GGA TCC GAA TTC TGC AGA AGA CTT ATG CTC GAG GGC CCA AAG CTT
GTT AAT TAA-3'

S-1105 (SEQ ID NO:13)

5'-TCGA GGG CCC GCA TAA GTC TTC-3'

S-1106 (SEQ ID NO:14)

5'-TCGA GAA GAC TTA TGC GGG CCC-3'

Oligos S-723 and S-724 were kinased, annealed together, and ligated to pBC.SK⁺ which had been digested with Kp_{ri}I and XbaI and treated with calf intestinal alkaline phosphatase, to create plasmid pSW143.1.

Oligos S-785 and S-786 were kinased, annealed together, and ligated to plasmid pSW143.1, which had been digested with XhoI and BamHI and treated with calf intestinal alkaline phosphatase, to create plasmid pSW164.02.

Oligonucleotides S-960, S-961, S-962, and S-963 were kinased and annealed together to form a duplex consisting of the four oligonucleotides. Plasmid pSW164.02 was digested with XhoI and SapI. The digested DNA was electrophoresed in an agarose gel, and the approximately 3045 bp product was purified from the appropriate gel slice. Plasmid pUC4K (from Pharmacia) was digested with PstI and electrophoresed in an agarose gel. The approx. 1240 bp product was purified from the appropriate gel slice. The two plasmid products (from pSW164.02 and pUC4K) were ligated together with the S-960/961/962/963 duplex to create plasmid pLCV1.

DNA from Adenovirus5 (New England Biolabs) was digested with PacI and Bsp120I, treated with calf intestinal alkaline phosphatase, and electrophoresed in an agarose gel. The approx. 2853 bp product was purified from the appropriate gel slice. This fragment was ligated to plasmid pLCV1 which had been digested with PacI and Bsp120I, to create plasmid pSW208.14.

Plasmid pSW208.14 was digested with XhoI, treated with calf intestinal alkaline phosphatase, and electrophoresed in an agarose gel. The approx. 5374 bp product was purified from the appropriate gel slice. This fragment was ligated to oligonucleotides S-1105 and S-1106 (which had been kinased and annealed together) to produce plasmid pLCV2, which contained the following elements (SEQ ID NO:15)

```

5' -...TTAATTAAGGA[ tag]GGGCCCCGATAAGTCTTC[stuffer]GGATCC ...-3'
3' -...AATTAATTCCT[ tag]CCCGGGCGTATTCAGAAG[stuffer]CCTAGG ...-5'
      ↑                ↑                ↑
      PacI             BbsI             BamHI

```

B. Construction of Tag Plasmid Library. A tag-plasmid library designated pBP9 was created as follows. A primer designated PEP-1 was synthesized having the sequence

5'-Fam-TGTGGCTTAATTAAGG (PEP-1, SEQ ID NO:16)

(Fam-TTP conjugate obtained from Perkin Elmer-Applied Biosystems Division). This PEP-1 primer was annealed to the combinatorial tag mixture from Example 1 (designated BP9), and the primer was extended by treatment with Sequenase DNA polymerase in the presence of the four standard dNTPs. The double-stranded product was purified, digested with PacI and Bsp120I, and ligated to the larger

fragment produced from pLCV2 by digestion with PacI and Bsp120I and removal of 5'-phosphate groups with calf intestinal alkaline phosphatase. The ligation product was electrophoresed in an agarose gel and purified from the gel slice using a QIAEX II kit (Qiagen). This ligated material was

used to transform electrocompetent *E. coli* TOP10F' (Invitrogen) or XL1BlueMRF' (Stratagene). Ligation and transformation conditions were optimized by conducting preliminary ligation reactions using 1 μ L vector fragment (~ 10 μ g), and either no insert, 1 μ L insert diluted 1:10, or 1 μ L non-diluted insert (~ 1 pmol), using a RAPID LIGATION KIT (Boehringer Mannheim). After ligation, the ligation mixture was used to transform electrocompetent cells, and transformants were plated (100 μ L neat, 100 μ L 1:10 dilution, and 100 μ L 1:100 dilution). Using this approach, the best vector/insert ratio was determined as the ratio that produced the highest number of colonies per initial DNA while maintaining a very low background. For library synthesis, the ligation conditions were scaled up as necessary.

Exemplary conditions are as follows:

200 μ L	vector (total obtained starting from 20 μ g plasmid)
X μ L	insert (PacI/Bsp120I digest)
50 μ L	10X ligation buffer
50 μ L	10 mM ATP
Y μ L	water
10 μ L	T4 DNA ligase (2,000,000 U/mL)

→ final volume = 500 μ L.

The ligation mixture was incubated overnight at 16°C, followed by extraction twice with one volume (500 μ L) TE-saturated phenol/chloroform/isoamyl alcohol (25:24:1), once with chloroform, followed by ethanol precipitation. After centrifugation, washing, and drying, the pellet was resuspended in 50 μ L water. Into each of several vials of electrocompetent cells (80-100 μ L cells) were added 1 to 2 μ L of ligation product. The following conditions were used for electroporation: 200 ohms, 25 μ F, 1800 V in a chilled 0.1 cm electroporation cuvette. Immediately after electroporation, 1 mL SOC broth (Sambrook et al., supra., at Appendix A.2 under SOC Medium) was added (room temperature), and the mixture was transferred to a 15 mL Falcon tube and shaken at 220 rpm at 37°C for 1 hour. Each transformation mixture was then added to 50 mL prewarmed broth (TB or LB + chloramphenicol) in a shaking flask. To determine titers, small aliquots of each transformation (5 μ L neat or diluted) were plated on LB agar plates containing 30 μ g/mL chloramphenicol to determine titer, while the remainder was inoculated into a liquid culture and shaken in an incubator overnight.

Transformations were repeated until the total number of independent transformants (clones) was estimated to be approximately 1.7×10^8 based on dilution analyses. This amount of transformants is equal to 10-fold the amount of potential tag variants produced by random combinatorial linkage of eight different tetrameric "word" sequences to produce tag sequences having a total length of eight words ($8^8 = 1.7 \times 10^8$). Plasmid DNA (pBP9) was extracted from the cultures and pooled. Note that cultures

could be combined before plasmid isolation only if they had similar titers. Otherwise, plasmids were isolated separately and then mixed together proportionately to their titers. Approximately 1.5 mg pBP9 was obtained.

C. Poly(A)⁺RNA Isolation

Poly(A)⁺RNA (approx. 30 µg from 5 x 10⁷ cells) was extracted from THP-1 cells using a FastTrack kit (Invitrogen) as recommended by the supplier. Poly(A)⁺RNA (approx. 15 µg from 5 x 10⁷ cells) was extracted from yeast cells using a STRAIGHT A's mRNA isolation system from Novagen. For cDNA synthesis, an ethanol suspension of polyA RNA was centrifuged in a cold microfuge at full speed for 30 minutes. The supernatant was removed and discarded, after which the pellet was recentrifuged briefly, and the supernatant was carefully removed by pipette. The sides of the tube were washed carefully with 0.75 mL of 70% ethanol, followed by centrifugation for 20 minutes. The supernatant was removed as before, to ensure that all liquid had been removed. The RNA pellet was resuspended in DEPC-treated water (32 µL was used for mRNA from 5 x 10⁷ mammalian cells; otherwise, the volume was adjusted accordingly). The resultant solution was spun to the bottom of the tube and placed on ice. RNA concentration was estimated by dilution in water, assuming 1.0 absorbance units at 260 nm (A₂₆₀) = 40 µg/mL RNA (the A₂₆₀/A₂₈₀ ratio should be 2.0). Gloves were worn at all times to avoid nuclease contamination.

D. cDNA Library Construction

First- and second-strand cDNA was synthesized using a cDNA Synthesis Kit (Stratagene) as recommended by the supplier, using RNase-free tubes, except that the following custom primer was used for first strand synthesis (RT primer, SEQ ID NO:17):

P2: 5'-biotin-GACATGCTGCATTGAGACGATTCTTTTTTTTTTTTTTTTTT

↑

BsmBI

where "V" represents a mixture of A, C, and G. In brief, the following solutions were added to a sterile 0.5 mL tube:

2.25 µL 10X first strand buffer
1.35 µL first strand methyl nucleotide mixture
1.0 µL RT primer (50 pmol/µL)
n µL DEPC-treated water (n calculated as below)
0.45 µL RNase block ribonuclease inhibitor (40 U/µL)

The resultant mixture was flicked to mix the components and then was spun to the bottom of the tube. To the mixture was added 2.5 µg poly(A)⁺RNA from above (m µL), where m is the volume containing

2.5 µg RNA, and n (the volume of DEPC-treated water) was calculated to produce a final volume of 21.8 µL (n+m = 16.8 µL). To the mixture was added 0.7 µL MMLV reverse transcriptase (50 U/µL). The mixture was gently vortexed or flicked, and then was spun to the bottom of the tube. The mixture was incubated at 37°C for 60 minutes in a heat block or PCR machine, and then placed on ice.

For second strand cDNA synthesis, the first-strand cDNA product (22.5 µL) was placed on ice, and the following components were added in order:

100 µL	10X second-strand buffer
3 µL	second-strand nucleotide mixture
57.0 µL	sterile water (not DEPC-treated)
1.0 µL	α - ³² P-dATP (10 µCi/µL, not more than 2 weeks old)

The mixture was flicked to mix the solution and then spun down briefly, followed by equilibration on ice for 5 minutes to reduce the number of hairpin structures. Next, the following enzymes were added:

1.0 µL	RNAse H (1.5 U/µL)
5.5 µL	DNA polymerase I (9.0 U/µL)

The resultant solution was mixed and spun briefly, without allowing the temperature to exceed 16°C.

The mixture was incubated at 16°C for 150 minutes (but not a longer time), after which it was placed on ice.

To the reaction tube was added 100 µL TE-saturated phenol/chloroform/isoamyl alcohol (25:24:1), and the mixture was vortexed thoroughly. The mixture was centrifuged for 5 minutes. The aqueous (upper) layer was carefully removed and transferred to a new tube without collecting any of the interface. 100 µL of chloroform:isoamyl alcohol (24:1) was added, and the mixture was vortexed thoroughly. The mixture was centrifuged for 5 minutes. The aqueous layer was collected and transferred to a new tube as before, and 1 µL of 5 M NaCl was added and vortexed.

The resultant double-stranded hemimethylated cDNA was size-fractionated on a Pharmacia SIZESEP 400 column (Cat. No. 27-5105). The column was equilibrated in STE buffer (1X STE = 100 mM NaCl, 20 mM Tris pH 7.5, 10 mM EDTA) by placing the SIZESEP gel in a spin column and allowing the buffer to drain out until the top of the gel bed was reached, followed by suspension of the gel bed in 2 mL TBE and allowing the buffer to drain to the top of the gel bed, and repeating the TBE suspension and draining steps two more times. The column was capped at both ends until use, to prevent drying. Immediately before use, the caps were removed, and the column was spun briefly at about 400 x g for 2 minutes to compact the gel and remove excess buffer. Next, the cDNA sample was applied carefully and slowly to the center of the flat surface at the top of the gel bed, so that the sample did not flow past the sides of the gel or through any cracks. The column was placed into a Falcon 2059 tube so that the lower tip of the column was placed over the top of a cap-less 1.5 mL microfuge tube to

collect column effluent. The column was spun in the Falcon tube at about 400 x g for 2 minute, so that synthesis primer and small cDNAs were retained in the column, while cDNAs of the desired length collected in the microfuge tube. The collected cDNA mixture was transferred to a new, capped tube. To the collected cDNA was added (optionally) 1 μ L PEI.LET PAINT (Novagen, Madison, WI), 0.1 volume of 3 M NaOAc, and 2.5 volumes EtOH. The resultant solution was stored at -70°C for at least 30 minutes or -20°C overnight. The double-stranded cDNA product had the following formula (SEQ ID NO:18):

```

5' -biot-GACATGCTGCATTGAGACGATTCTTTTTTTTTTTTTTTTTTVXXX ... XGATCXXX
      CTGTACGACGTAACTCTGCTAAGAAAAAAAAAAAAAAAAAABXXX ... XTAGXXX
                ↑                               ↑
              BsmBI                           DpnII

```

where the X's indicate nucleotides in the cDNAs, V represents A, C or G, and B represents C, G or T.

Note that the RT primer sequence was selected to give a BsmBI site in the cDNAs which results in a 5'-GCAT overhang upon digestion with BsmBI.

After spinning the ethanol/NaOAc/cDNA solution for 30 minutes in a cold microfuge and washing with 70% ethanol as before, the size-fractionated cDNA was digested to completion with DpnII by resuspending the cDNA pellet in a solution of 170 μ L water, 20 μ L 10X DpnII buffer, and 10 μ L DpnII (10 U/ μ L), followed by incubation at 37°C for 2 hours.

The biotinylated fragments were purified using Dynal M-280 streptavidin beads. In preparation for biotin capture, the magnetic streptavidin beads were resuspended by vortexing, and 100 μ L bead (1 mg) was transferred to a fresh 1.5 mL microfuge tube. The tube was placed in a magnetic particle concentrator (MPC) for at least 60 seconds to allow the beads to pellet near the magnet. The supernatant was removed and discarded while the tube was in the MPC. To the tube was added 100 μ L 1X B&W buffer (2X B&W buffer = 20 mM Tris-HCl pH 8.0, 2 mM EDTA, and 2 M NaCl), and the suspension was vortexed, placed in the MPC to concentrate the magnetic beads, and the supernatant was removed as before. This washing procedure was repeated twice more. At no time were the beads allowed to dry during the above procedure.

To the DpnII digest from above (200 μ L) was added 200 μ L of 2X B&W buffer. This mixture was transferred to a tube containing the prepared magnetic streptavidin beads, and the beads were resuspended by flicking the tube. The tube was incubated in a Thermomixer at 25°C for 30 minutes so that the beads were fully suspended at all times to help ensure biotin capture. Next, the tube was placed in the MPC, and the supernatant was withdrawn and stored at -20°C. The beads were washed five times with 400 μ L X B&W buffer, and the supernatants were analyzed to verify that little or no radioactive counts were present after the third or fourth wash.

To remove the tagged cDNA fragments, the following steps were performed::

1. Resuspend beads in a mixture of 20 μ L 10X NEB 3 Buffer (New England Biolabs) and 168 μ L water.
2. Add 2 μ L bovine serum albumin 100X stock (10 mg/mL BSA, New England Biolabs).
3. Add 10 μ L BsmBI (4 U/ μ L).
4. Shake tube in Thermomixer at 55°C for 2 hours, so that beads remain fully suspended.
5. Add 7 μ L BsmBI 10X stock solution, and shake tube at 55°C for 1-2 additional hours.
6. Place tube in MPC for 60 seconds. Collect supernatant, which contains released tag sequences.
7. Add 2 μ L PELLET PAINT. Extract once with 200 μ L phenol/chloroform and once with 200 μ L chloroform.

To the resultant aqueous layer was added 20 μ L 3 M NaOAc and 500 μ L EtOH. This mixture was stored at -20°C overnight or at -70°C for 30 minutes. The solution was then spun in a microfuge for at least 30 minutes. The supernatant was removed and discarded, and the pellet was washed with, and centrifuged in, 0.5 mL of 70% EtOH. After the supernatant was removed, the cDNA pellet was resuspended in 10 μ L water. The released cDNA fragment mixture had the following formula (SEQ ID NO:19):

5' -GCATTGAGACGATTCTTTTTTTTTTTTTTTTTTVXXX ... X-3'
 3' -ACTCTGCTAAGAAAAAAAAAAAAAAAAAABXXX ... XCTAG-5'

The pBP9 tag-vector from above was digested with BbsI and BamHI, treated with calf intestinal alkaline phosphatase, and purified by electrophoresis in an agarose gel. The larger fragment (approximately 3.15 kb) was purified from the gel and combined with the cDNA fragment mixture for ligation. Note that the vector has been engineered so that BbsI digestion produces an end compatible with the BsmBI-digested end of the cDNAs. The purified vector fragment was ligated to the cDNA mixture prepared as above.

To produce a vector library of tagged cDNA inserts, the ligated vector-insert mixture was used to transform electrocompetent E. coli TOP10 cells (Invitrogen). A small quantity of the transformation was plated on LB agar plates containing 30 μ g/mL chloramphenicol to determine titer. Aliquots comprising approximately 1.6×10^5 clones were used to inoculate liquid cultures in order to expand the library. Plasmid DNA was extracted from these cultures and stored.

E. Hybridization of Tagged Fragments to Immobilized Tag Complements

The tagged DNA inserts can be captured or sorted by hybridization to an array of Immobilized tag complements such as described above.

Preferably, the tag cDNA conjugates are amplified from the vectors by PCR, using a conventional

protocol such as the following. For each of 8 replicate PCRs, the following reaction components are combined: 1 μ L vector DNA (125 ng/ μ L for a library, 10^9 copies for a single clone); 10 μ L 10X KLENTAQ Buffer (Clontech Labs, Palo Alto, CA); 0.25 μ L biotinylated 20-mer "forward" PCR primer (1 nmol/ μ L); 0.25 μ L FAM-labeled 20-mer "reverse" PCR primer (1 nmol/ μ L); 1 μ L 25 mM dATP, dGTP, dTTP, and 5-methyl-dCTP (total dNTP concentration 100 mM); 5 μ L DMSO; 2 μ L 50X KLENTAQ enzyme; and 80.5 μ L water, for a total volume of 100 μ L. The PCR reactions are run in an MJR DNA Engine (MJ Research), or like thermocycler, with the following protocol: (1) 94°C for 4 min; (2) 94°C for 30 sec; (3) 67°C for 3 min; (4) 8 cycles of steps 2 and 3; (5) 94°C for 30 sec; (6) 64°C for 3 min; (7) 22 cycles of steps 5 and 6; (8) 67°C for 3 min; and (9) hold at 4°C.

The 8 PCR mixtures are pooled and 700 μ L phenol is added at room temperature, after which the combined mixture is vortexed for 20-30 sec and then centrifuged at high speed for 3 min (e.g., 14,000 rpm in an Eppendorf bench top centrifuge, or like instrument). The supernatant is removed and combined with 700 μ L chloroform (24:1 mixture of chloroform:isoamyl alcohol) in a new tube, vortexed for 20-30 sec, and centrifuged for 1 min, after which the supernatant is transferred to a new tube and combined with 80 μ L 3 M sodium acetate and 580 μ L isopropanol. After centrifuging for 20 min, the supernatant is removed and 1 mL 70% ethanol is added. The mixture is centrifuged for 5-10 min, after which the ethanol is removed, and the precipitated DNA is dried in a microcentrifuge.

After resuspension, the cDNA is purified on avidinated magnetic beads (Dyna) using the manufacturer's recommended protocol. The cDNA is then digested with PaeI (1 unit of enzyme per μ g DNA), also using the manufacturer's recommended protocol (New England Biolabs, Beverly, MA). The cleaved DNA is extracted with phenol/chloroform followed by ethanol precipitation. The tags of the tag-cDNA conjugates are rendered single-stranded by adding 2 units of T4 DNA polymerase (New England Biolabs) per μ g of streptavidin-purified DNA. 150 μ g of streptavidin-purified DNA is resuspended in 200 μ L water and combined with the following reaction components: 30 μ L 10X NEB Buffer No. 2 (New England Biolabs); 9 μ L 100 mM dGTP; 30 μ L T4 DNA polymerase (10 U/ μ L); and 31 μ L water; to give a final reaction volume of 300 μ L. After incubation for 1 hour at 37°C, the reaction is stopped by adding 20 μ L 0.5 M EDTA, and the T4 DNA polymerase is inactivated by incubating the reaction mixture for 20 min at 75°C. The tag-cDNA conjugates are purified by phenol/chloroform extraction and ethanol precipitation.

For hybridization of tag-cDNA conjugates to immobilized tag complements, the tag-cDNA conjugates prepared as above are suspended in 50 μ L water, and the resulting mixture is combined with 40 μ L 2.5X hybridization buffer. The combined mixture is filtered through a SPIN-X spin column (0.22 μ m) using a conventional protocol to give a filtrate containing the tag-cDNA conjugates (5 mL of 2.5X hybridization buffer consists of 1.25 mL 0.1 M sodium phosphate, pH 7.2, 1.25 mL 5 M NaCl, 0.25 mL, 0.5% TWEEN 20, 1.5 mL 25% dextran sulfate, and 0.75 mL water). The number of beads in a

5 given volume is readily estimated with a hemocytometer. Approximately 1.8×10^7 beads derivatized with tag complements as above are dissolved in 10 μ L TE/TWEEN buffer (TE with 0.1% TWEEN 20) and centrifuged so that the beads form a pellet, from which the TE/TWEEN is removed. To the beads, 10 25 μ L of 1X hybridization buffer (10 mM sodium phosphate, pH 7.2, 500 mM NaCl, 0.01% TWEEN 20, and 3% dextran sulfate) is added and the mixture is vortexed to fully resuspend the beads, after 5 which the mixture is centrifuged so that the beads form a pellet, and the supernatant is removed.

The tag-DNA conjugates from the above filtrate are incubated at 75°C for 3 min, and then are 15 combined with the beads. The mixture is vortexed to fully resuspend the beads. The resulting mixture is further incubated at 75°C with vortexing for approximately three days (60 hours). After 10 hybridization, the mixture is centrifuged for 2 min and the supernatant is removed. The beads are washed twice with 500 μ L TE/TWEEN 20, and are resuspended in 500 μ L 1X NEB buffer No. 2 with 20 0.1% TWEEN 20. The beads are incubated at 64°C in this solution for 30 min, after which the mixture is centrifuged so that the beads form a pellet. The supernatant is removed, and the beads are resuspended in 500 μ L TE/TWEEN. The hybridized conjugates may then be analyzed by any method 15 known in the art or discussed herein.

Example 3

Succinate-Based Linking Moieties

The following procedure was used to make GMA beads derivatized with a cleavable succinate 30 ester linking moiety (10%) and a non-cleavable succinate amide linking moiety (90%).

Succinate Ester. Succinic anhydride (240 mg, 2.4 mmol) was added in portions over 30 min to a stirred solution of 5'-O-dimethoxytrityl thymidine (3 mol) in anhydrous pyridine (6 mL) containing 4-dimethylaminopyridine (180 mg, 1.5 mmol). The reaction was stirred overnight and monitored by thin 35 layer chromatography using chloroform:methanol 9:1 (v:v). The mixture was dried to a gum under reduced pressure. Residual pyridine was removed by co-evaporation with dry toluene (3 x 20 mL). The product was dissolved in dichloromethane (20 mL) and washed with ice-cold 10% aqueous citric acid (2 x 15 mL) and then with water (2 x 15 mL). The organic phase was dried over anhydrous sodium 40 sulfate and evaporated under reduced pressure. The resultant foam was dissolved in dichloromethane (10 mL) and precipitated at room temperature into rapidly stirred hexane (250 mL). After the mixture was centrifuged, the supernatant was decanted. The precipitate was dried under reduced pressure to 30 give a yield of 75-80% (ester product).

Succinamide. The above procedure for succinylation was repeated with an identical amount of 5'-O-dimethoxytrityl-3'-deoxy-3'-amino thymidine instead of 5'-O-dimethoxytrityl thymidine, to form the corresponding succinamide product (amide product).

Attachment to Support. 0.821 g (1.1 mmol) of the ester product or amide product was dissolved 50 and stirred for 2 min in a mixture of 5 mL 0.2 M HOBt (1-hydroxybenzotriazole hydrate, 0.27 g in a

5 mixture of 4.7 mL DMSO (dimethyl sulfoxide) and 4.7 mL NMP (N-methyl pyrrolidone)) and 5 mL of
0.2 M HBTU (O-benzotriazole-1-yl-N,N',N'-tetramethyluronium hexafluorophosphate, 1.03 g in a
mixture of 1.4 mL N,N-diisopropylethylamine, 9.3 mL DMSO and 9.3 mL NMP). Amino-derivatized
10 GMA beads (5.5g, 5.6 μ m diameter) was stirred in 10 mL DMF. To this slurry was added all of the
5 amide product from above and an amount of ester product equal to 1/9 of the amide product (9:1 molar
ratio). The slurry was placed in a screw cap falcon tube and gently shaken for 2 hours. The mixture
was then filtered and washed successively with 20 mL each of DMF, acetonitrile, methanol, and ether.
15 The dried beads were then ready for synthesis of tag complements.

Although the invention has been described with respect to particular embodiments, it will be
10 appreciated that various modifications can be made without departing from the spirit of the invention.

IT IS CLAIMED:

1. A method of synthesizing a repertoire of oligonucleotide tags, the method comprising:
synthesizing a plurality of different sequence oligonucleotide populations on one or more solid phase supports, such that each population is located at a spatially discrete region relative to the other populations, and the oligonucleotides in each population comprise a tag-complement sequence that is the same for every oligonucleotide in a given population,
cleaving a fraction of the oligonucleotides from each population on the one or more supports, to release a mixture of different-sequence tag-complement oligonucleotides, and
annealing a primer to each tag-complement oligonucleotide and extending each annealed primer to form a duplex comprising a tag-complement strand and a complementary tag strand, such that the tag-complement strands or the duplexes thus formed comprise an oligonucleotide tag repertoire.
2. The method of claim 1, wherein said oligonucleotides are bound to the one or more supports by their 3'-termini, and each oligonucleotide contains a universal primer-binding sequence on the 3'-side of the tag complement sequence.
3. The method of claim 1, wherein said fraction is from 10 to 30%.
4. The method of claim 1, wherein a selected fraction of each population of synthesized oligonucleotides is bound to the one or more supports via base-cleavable linkages, and said cleaving includes subjecting the immobilized oligonucleotides to basic conditions effective to cleave said fraction of oligonucleotides from the one or more supports.
5. The method of claim 1, wherein the tag complement sequence in each said oligonucleotide is flanked by first and second endonuclease restriction sites which may be the same or different.
6. The method of claim 1, wherein said repertoire of oligonucleotide tag complements contains at least 1000 different-sequence tag complements.
7. The method of claim 1, wherein said repertoire of oligonucleotide tag complements contains at least 10,000 different-sequence tag complements.
8. The method of claim 1, wherein said tag complement sequences are from 12 to 60 nucleotides in length.
9. The method of claim 1, wherein said tag complement sequences are from 18 to 40 nucleotides in length.

10. The method of claim 1, wherein said one or more solid phase supports are microparticles.

11. The method of claim 10, wherein said microparticle(s) have diameters of from about 5 to about 40 μm .

12. The method of claim 1, wherein said tag complement sequences each contain a plurality of segments that are (i) three to nine nucleotides in length and (ii) selected from a minimally cross-hybridizing set of tag complement sequences.

13. A repertoire of tag oligonucleotides prepared by the method of claim 1.

14. A method of forming a tag-vector library comprising multiple members from a tag repertoire, the method comprising the steps of:

synthesizing a plurality of oligonucleotide populations on one or more solid phase supports, such that each population is located at a spatially discrete region relative to the other populations, and the oligonucleotides in each population comprise a tag-complement sequence that is the same for every oligonucleotide in a given population,

cleaving a fraction of the oligonucleotides from each population on the one or more supports, to release a mixture of different-sequence tag-complement oligonucleotides,

annealing a primer to each tag-complement oligonucleotide and extending each annealed primer to form a duplex comprising a tag-complement strand and a complementary tag strand, such that the tag-complement strands or the duplexes thus formed comprise an oligonucleotide tag repertoire, and inserting said duplexes by ligation into multiple copies of a selected vector, to form a tag-vector library comprising members of said tag repertoire.

15. A tag-vector library formed by the method of claim 14.

16. A method of forming a library of tagged polynucleotide fragments, the method comprising the steps of:

synthesizing a plurality of oligonucleotide populations on one or more solid phase supports, such that each population is located at a spatially discrete region relative to the other populations, and the oligonucleotides in each population comprise a tag-complement sequence that is the same for every oligonucleotide in a given population,

cleaving a fraction of the oligonucleotides from each population on the one or more supports, to release a mixture of different-sequence tag-complement oligonucleotides,

annealing a primer to each tag-complement oligonucleotide and extending each annealed primer to form a duplex comprising a tag-complement strand and a complementary tag strand, such that the tag-complement strands or the duplexes thus formed comprise an oligonucleotide tag repertoire,

5 inserting said duplexes by ligation into multiple copies of a selected vector, to form a tag-vector library comprising members of said tag repertoire, and

10 combining said tag-vector library with a mixture of different polynucleotide fragments under ligation conditions effective to insert a polynucleotide fragment into each tag-vector at a site adjacent to a tag-sequence in each vector, thereby forming a library of tagged polynucleotide fragments.

17. A library of tagged polynucleotide fragments formed by the method of claim 16.

18. A system for sorting polynucleotides, said system comprising:


10 one or more solid phase supports on which are attached a plurality of oligonucleotide populations, such that each population is located at a spatially discrete region on said one or more supports relative to the other populations, and the oligonucleotides in each population comprise a tag-complement sequence that is the same for every oligonucleotide in a given population, and

15 a tag composition selected from the group consisting of a tag repertoire prepared by the method of claim 1, a tag-vector library prepared by the method of claim 14, or a library of tagged polynucleotide fragments prepared by the method of claim 16, which tag composition is prepared from said one or more supports recited in the preceding paragraph.


19. A solid phase bead comprising a population of oligonucleotides attached to the bead, said population comprising first and second classes of oligonucleotides which contain identical oligonucleotide sequences, wherein the oligonucleotides in said first class contain a cleavable linking moiety that permits selective cleavage of the first class of oligonucleotides from the support, without significantly cleaving the second class of oligonucleotides.

20. A mixture of solid phase beads, said mixture comprising a plurality of beads, each having a population of oligonucleotides attached thereto, wherein each population comprises first and second classes of oligonucleotides such that the oligonucleotides in the first class contain a cleavable linking moiety that permits selective cleavage of the first class of oligonucleotides from the support, without significantly cleaving the second class of oligonucleotides, and the oligonucleotides in both classes in each population comprise a tag-complement sequence that is the same for every oligonucleotide in a given population.

1/2

**Fig. 1**

2/2

**Fig. 2**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/25680**A. CLASSIFICATION OF SUBJECT MATTER**IPC(7) : C12Q 1/68; C07H 21/02; C12N 19/34; C12P 15/00
US CL : 435/6, 91.52; 536/24.2, 24.3, 26.6; 935/77, 78

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.52; 536/24.2, 24.3, 26.6; 935/77, 78

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST 1.2, MEDLINE, BIOSIS, SCISEARCH, USPATFULL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,E	US 6,013,445 A (ALBRECHT et al) 11 January 2000, see entire document.	1-13 and 18
X	US 5,763,175 A (BRENNER) 09 June 1998, see the entire document.	1-13 and 18
X	US 5,780,231 A (BRENNER) 14 July 1998, see the entire document.	1-13 and 18
X,E	US 5,962,228 A (BRENNER) 05 October 1999.	1-13 and 18
X	WO 96/41011 A1 (SPECTRAGEN, INC.) 19 December 1996, see the entire document.	1-13 and 18

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 JANUARY 2000

Date of mailing of the international search report

09 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

P. PONNALURI

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/25680

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-13 and 18

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/25680

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-13 and 18, drawn to a method of synthesizing a repertoire of oligonucleotide tags and a system of sorting polynucleotide fragments.

Group II, claim(s) 14-15, drawn to a method of forming a tag-vector library comprising multiple members of tag repertoire and a tag-vector library.

Group III, claim(s) 16-17, drawn to a method of forming a library of tagged polynucleotide fragments and a library of tagged polynucleotide fragments.

Group IV, claim(s) 19-20, drawn to a solid phase bead comprising a population of oligonucleotides attached to the bead and a mixture of solid phase beads.

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of group I is a method of making a repertoire of oligonucleotide tags; the special technical feature of group II is a method of making a vector library comprising tag repertoire; the special technical feature of group III is a method of making a library of tagged polynucleotide fragments; and the special technical feature of group IV is solid phase beads comprising a population of oligonucleotide, which are attached to the beads by cleavable linkers. Since the special technical feature of group I is not present in groups II-IV and the special technical feature of groups II-IV is not present in the group I, unity of the invention is lacking.